

Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelsystem.org.



Overview for Request: cder_mpl2r_wp012, Report 3 of 4 (Incident Cohorts)

Request ID: cder_mpl2r_wp012_nsdp_v01

Request Description: In this request, we estimate the longitudinal trend in incident use of long-acting beta-2 agonist (LABA) with and without a long-term asthma controller medication (ACM) among asthma patients in the Sentinel Distributed Database (SDD). This is report 3 of 4 of the incident cohort reports and focuses on longitudinal rates of LABA users in the presence of ACM or fixed dose combination LABAs (FDC-LABA) dispensings among LABA-naive patients with poorly-controlled asthma. This definition of poorly-controlled asthma requires three instances of short-acting beta-2 agonist (SABA) canisters in the baseline period.

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis (CIDA) tool, version 9.3.1

Data Source: We distributed this request on April 6, 2020 and queried data from January 1, 2006 through September 30, 2015 in 16 Data Partners contributing to the SDD. See Appendix A for a list of the latest dates of available data for each Data Partner.

<u>Study Design</u>: We followed incident users of LABAs, consisting of both single ingredient LABAs (SI-LABAs) and FDC-LABAs, on their exposed time until censoring criteria were met. We created fifteen cohorts consisting of these LABA users who also had overlapping days supply and/or dispensing date with either SI-LABA or non-LABA ACM episodes. Non-LABA ACM (referred to as simply "ACM" below) are defined as inhaled corticosteroids (ICS), leukotriene modifiers, chromones, oral systemic corticosteroids, immunomodulators, and methylxanthines. We calculated rates based off counts from these cohorts. These rates were then used to create an interrupted time series (ITS) regression model. This is report 3 of 4 and contains results for cohorts 8-11.

Exposures of Interest: We defined exposure of interest as the first qualifying dispensing of any LABA product. New use is defined as having no prior use of any LABA product in the 183 days prior to index date. We defined each exposure and exposure incidence using National Drug Codes (NDCs) observed in the outpatient pharmacy dispensings. Please see Appendix B for a list of generic and brand names of medical products used to define exposures.

Inclusion and Exclusion Criteria: All cohorts required exclusion of chronic obstructive pulmonary disease (COPD), cystic fibrosis, bronchiectasis, pulmonary hypertension or embolism, or bronchopulmonary dysplasia in the 365 days prior to and including index date. Additionally, all cohorts required inclusion of an asthma diagnosis. Cohorts 8-15 also required fulfillment of the poorly controlled asthma inclusion criteria. For cohort 1 only, asthma is defined as one asthma diagnosis in the 365 days prior to index date in any care setting. Otherwise, asthma is defined as either one asthma diagnosis in either an inpatient (IP) or emergency department (ED) care setting, or two instances of asthma diagnosis in either an ambulatory visit (AV) or other ambulatory (OA) care setting in the 365 days prior to or including index date. An individual is considered to have poorly controlled asthma if any of the following inclusion criteria are fulfilled:

1) One instance of ICS or leukotriene modifiers in the 90 days prior to index date

- 2) One instance of asthma diagnosis in the 90 days prior to index date in either IP or ED care setting
- 3) Two instances of oral corticosteroids with dispensings of 21 days supply or smaller in the 90 days prior to index date
- 4) (for cohorts 8-11 only) Three instances of SABA canisters dispensed in the 183 days prior to index date

We defined all inclusion and exclusion criteria using NDCs or International Classification of Diseases, Ninth Revision (ICD-9-CM) diagnosis codes. Please refer to Appendix C for a list of diagnosis codes and Appendix D for a list of generic and brand names of medical products used to define inclusion and exclusion criteria.



Overview for Request: cder_mpl2r_wp012, Report 3 of 4 (Incident Cohorts)

Overlap Criteria: Only users who fulfill overlap criteria specified below enter the cohorts.

<u>Report 3</u>: In this report, we include users in cohorts 8-11 if there is ACM use or FDC-LABA use present during incident LABA use. ACM and FDC-LABA use are defined as any valid exposure episode during the query period, where episodes are created with an episode gap that is 25% of the days supply of the previous dispensing. FDC-LABA use must be preceded by continuous enrollment in medical and prescription drug insurance plans for at least 365 days prior to dispensing date, during which gaps in coverage of up to 45 days were allowed; and do not have chronic obstructive pulmonary disease (COPD), cystic fibrosis, bronchiectasis, pulmonary hypertension or embolism, or bronchopulmonary dysplasia in the 365 days prior to and including FDC-LABA dispensing date. Additional differences are detailed below:

Cohort 8) Users are included in Cohort 8 if there is at least one day of ACM or FDC-LABA use during the incident LABA exposure episode.

Cohort 9) Users are included in Cohort 9 if there is either ACM or FDC-LABA use for at least 50% the duration of the incident LABA exposure episode.

Cohort 10) Users are included in Cohort 10 if there is either ACM or FDC-LABA use for at least 75% the duration of the incident LABA exposure episode.

Cohort 11) Users are included in Cohort 11 if there is either ACM or FDC-LABA use on incident LABA dispensing date.

Follow-Up Time: We determined follow-up time based on the length of exposure episodes, which was defined using days supply information recorded in the outpatient pharmacy dispensings to create any period of continuous exposure. We considered an exposure episode continuous if gaps in days covered by days supply were less than 25% of the previous dispensing's days supply. This query analyzed only the first valid exposure episode per eligible member. Follow-up began on the index date and continued until the last day of supply of the last dispensing, or until the first occurrence of any of the following: 1) disenrollment; 2) death; 3) the end date of the data provided by each Data Partner; or 4) the end of the query period (September 30, 2015).

<u>Analysis:</u> We fitted an autoregression piecewise linear model describing the change of an observed rate over exposure time in months with an autoregression lag of 12 months and an intervention date on June 2, 2010, which is the date of the LABA drug safety communication (DSC)¹ issued by the US Food and Drug Administration (FDA). When determining the number of users in any given month for rate calculation purposes, exposure episode follow-up time is truncated on intervention date. The rate modeled is described below:

Cohort 8) The rate used for the ITS regression model is the number of incident LABA users with at least one day of overlapping ACM or FDC-LABA use among LABA-naive poorly-controlled asthma patients, defined with SABA canisters.

Cohort 9) The rate used for the ITS regression model is the number of incident LABA users with at least 50% adherence to ACM or FDC-LABA use among LABA-naive poorly-controlled asthma patients, defined with SABA canisters.

Cohort 10) The rate used for the ITS regression model is the number of incident LABA users with at least 75% adherence to ACM or FDC-LABA use among LABA-naive poorly-controlled asthma patients, defined with SABA canisters.

Cohort 11) The rate used for the ITS regression model is the number of incident LABA users with same-day ACM or FDC-LABA dispensing among LABA-naive poorly-controlled asthma patients, defined with SABA canisters.

ITS regression is performed for overall population and in subgroups defined by: age groups (18-45, 46-64, 65+ years), sex (male, female), and race (American Indian or Alaskan native, Asian, black or African American, native Hawaiian or other Pacific islander, white, or unknown).

Limitations: 1) As with all observational studies, this evaluation is limited in its ability to control for all sources of potential bias. 2) Algorithms to define exposures, inclusion and exclusion criteria, and covariates are imperfect and may be misclassified. Therefore, data should be interpreted with this limitation in mind. 3.) Race data may not completely captured at individual Data Partner. 4.) Piecewise linear regression models were used for the ITS analysis. Seasonality in data was not factored into adjustment.

Please see Appendix E for the specifications of parameters used in the analyses for this request



Overview for Request: cder_mpl2r_wp012, Report 3 of 4 (Incident Cohorts)

<u>Notes:</u> Please contact the Sentinel Operations Center (info@sentinelsystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (https://dev.sentinelsystem.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse).

¹Food and Drug Administration (FDA). 2010 Drug Safety Communications. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/2010-drug-safety-communications. Last updated March 8, 2016. Accessed May 7, 2020.



Table of Content

<u>Glossary</u> List of Terms Found in this Report and their Definitions

- Table 1aParameter Estimates from the Segmented Regression Model of Monthly Proportion of Incident Long-Acting Beta-2
Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC)
LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database
(SDD) after June 2, 2010
- Table 1bParameter Estimates from the Segmented Regression Model of Monthly Proportion of Incident Long-Acting Beta-2
Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC)
LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database
(SDD) after June 2, 2010, by Age Group
- Table 1cParameter Estimates from the Segmented Regression Model of Monthly Proportion of Incident Long-Acting Beta-2Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC)LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database(SDD) after June 2, 2010, by Sex
- Table 1dParameter Estimates from the Segmented Regression Model of Monthly Proportion of Incident Long-Acting Beta-2
Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC)
LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database
(SDD) after June 2, 2010, by Race
- Table 1eParameter Estimates from the Segmented Regression Model of Monthly Proportion of Incident Long-Acting Beta-2Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-DoseCombination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the SentinelDistributed Database (SDD) after June 2, 2010
- Table 1fParameter Estimates from the Segmented Regression Model of Monthly Proportion of Incident Long-Acting Beta-2
Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose
Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel
Distributed Database (SDD) after June 2, 2010, by Age Group
- Table 1gParameter Estimates from the Segmented Regression Model of Monthly Proportion of Incident Long-Acting Beta-2Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-DoseCombination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the SentinelDistributed Database (SDD) after June 2, 2010, by Sex
- Table 1hParameter Estimates from the Segmented Regression Model of Monthly Proportion of Incident Long-Acting Beta-2Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-DoseCombination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the SentinelDistributed Database (SDD) after June 2, 2010, by Race
- Table 1iParameter Estimates from the Segmented Regression Model of Monthly Proportion of Incident Long-Acting Beta-2
Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose
Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel
Distributed Database (SDD) after June 2, 2010
- Table 1jParameter Estimates from the Segmented Regression Model of Monthly Proportion of Incident Long-Acting Beta-2
Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose
Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel
Distributed Database (SDD) after June 2, 2010, by Age Group



Table	of	Contents
-------	----	----------

- Table 1kParameter Estimates from the Segmented Regression Model of Monthly Proportion of Incident Long-Acting Beta-2
Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose
Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel
Distributed Database (SDD) after June 2, 2010, by Sex
- Table 11Parameter Estimates from the Segmented Regression Model of Monthly Proportion of Incident Long-Acting Beta-2Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-DoseCombination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the SentinelDistributed Database (SDD) after June 2, 2010, by Race
- Table 1mParameter Estimates from the Segmented Regression Model of Monthly Proportion of Incident Long-Acting Beta-2
Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose
Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel
Distributed Database (SDD) after June 2, 2010
- Table 1nParameter Estimates from the Segmented Regression Model of Monthly Proportion of Incident Long-Acting Beta-2
Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose
Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel
Distributed Database (SDD) after June 2, 2010, by Age Group
- Table 10Parameter Estimates from the Segmented Regression Model of Monthly Proportion of Incident Long-Acting Beta-2
Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose
Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel
Distributed Database (SDD) after June 2, 2010, by Sex
- Table 1pParameter Estimates from the Segmented Regression Model of Monthly Proportion of Incident Long-Acting Beta-2
Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose
Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel
Distributed Database (SDD) after June 2, 2010, by Race
- Table 2aAbsolute and Relative Changes in Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-NaivePatients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010 Comparedwith Expected Rates Derived from Baseline Trend
- Table 2bAbsolute and Relative Changes in Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-NaivePatients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010 Comparedwith Expected Rates Derived from Baseline Trend, by Age Group
- Table 2cAbsolute and Relative Changes in Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-NaivePatients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010 Comparedwith Expected Rates Derived from Baseline Trend, by Sex
- Table 2dAbsolute and Relative Changes in Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-NaivePatients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010 Comparedwith Expected Rates Derived from Baseline Trend, by Race
- Table 2eAbsolute and Relative Changes in Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least
50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA
Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD)
after June 2, 2010 Compared with Expected Rates Derived from Baseline Trend



Table of Conte	nts
----------------	-----

- Table 2fAbsolute and Relative Changes in Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABADispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD)after June 2, 2010 Compared with Expected Rates Derived from Baseline Trend, by Age Group
- Table 2gAbsolute and Relative Changes in Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABADispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD)after June 2, 2010 Compared with Expected Rates Derived from Baseline Trend, by Sex
- Table 2hAbsolute and Relative Changes in Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least
50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA
Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD)
after June 2, 2010 Compared with Expected Rates Derived from Baseline Trend, by Race
- Table 2iAbsolute and Relative Changes in Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least
75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA
Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD)
after June 2, 2010 Compared with Expected Rates Derived from Baseline Trend
- Table 2jAbsolute and Relative Changes in Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABADispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD)after June 2, 2010 Compared with Expected Rates Derived from Baseline Trend, by Age Group
- Table 2kAbsolute and Relative Changes in Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least
75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA
Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD)
after June 2, 2010 Compared with Expected Rates Derived from Baseline Trend, by Sex
- Table 21Absolute and Relative Changes in Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least
75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA
Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD)
after June 2, 2010 Compared with Expected Rates Derived from Baseline Trend, by Race
- Table 2mAbsolute and Relative Changes in Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day
Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-
Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010
Compared with Expected Rates Derived from Baseline Trend
- Table 2nAbsolute and Relative Changes in Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day
Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-
Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010
Compared with Expected Rates Derived from Baseline Trend, by Age Group
- Table 20Absolute and Relative Changes in Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day
Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-
Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010
Compared with Expected Rates Derived from Baseline Trend, by Sex
- Table 2pAbsolute and Relative Changes in Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day
Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-
Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010
Compared with Expected Rates Derived from Baseline Trend, by Race



	Table of Contents
Figure 1	Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010
<u>Figure 2</u>	Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010 where Age Group = 18-45
Figure 3	Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010 where Age Group = 46-64
<u>Figure 4</u>	Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010 where Age Group = 65+
<u>Figure 5</u>	Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010 where Sex = Female
<u>Figure 6</u>	Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010 where Sex = Male
<u>Figure 7</u>	Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010 where Race = Unknown
<u>Figure 8</u>	Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010 where Race = American Indian/Alaska Native
<u>Figure 9</u>	Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010 where Race = Asian
<u>Figure 10</u>	Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010 where Race = Black/African American
<u>Figure 11</u>	Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010 where Race = Native Hawaiian/Other Pacific Islander
Figure 12	Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010 where Race = White
<u>Figure 13</u>	Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010
Figure 14	Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010 where Age Group = 18-45



	Tab	le	of	Contents	;
--	-----	----	----	----------	---

- Figure 15Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma
Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with
Poorly Controlled Asthma Before and After June 2, 2010 where Age Group = 46-64
- **Figure 16** Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010 where Age Group = 65+
- **Figure 17** Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010 where Sex = Female
- **Figure 18** Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010 where Sex = Male
- **Figure 19** Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010 where Race = Unknown
- **Figure 20** Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010 where Race = American Indian/Alaska Native
- **Figure 21** Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010 where Race = Asian
- **Figure 22** Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010 where Race = Black/African American
- Figure 23Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma
Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with
Poorly Controlled Asthma Before and After June 2, 2010 where Race = Native Hawaiian/Other Pacific Islander
- **Figure 24** Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010 where Race = White
- **Figure 25** Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010
- Figure 26Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma
Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with
Poorly Controlled Asthma Before and After June 2, 2010 where Age Group = 18-45
- Figure 27Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma
Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with
Poorly Controlled Asthma Before and After June 2, 2010 where Age Group = 46-64
- Figure 28Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma
Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with
Poorly Controlled Asthma Before and After June 2, 2010 where Age Group = 65+



Table of contents	Table	of	Contents
-------------------	-------	----	----------

- Figure 29Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma
Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with
Poorly Controlled Asthma Before and After June 2, 2010 where Sex = Female
- **Figure 30** Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010 where Sex = Male
- Figure 31Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma
Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with
Poorly Controlled Asthma Before and After June 2, 2010 where Race = Unknown
- **Figure 32** Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010 where Race = American Indian/Alaska Native
- **Figure 33** Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010 where Race = Asian
- **Figure 34** Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010 where Race = Black/African American
- **Figure 35** Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010 where Race = Native Hawaiian/Other Pacific Islander
- **Figure 36** Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010 where Race = White
- **Figure 37** Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010
- Figure 38Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller
Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly
Controlled Asthma Before and After June 2, 2010 where Age Group = 18-45
- **Figure 39** Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010 where Age Group = 46-64
- Figure 40Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller
Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly
Controlled Asthma Before and After June 2, 2010 where Age Group = 65+
- Figure 41Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller
Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly
Controlled Asthma Before and After June 2, 2010 where Sex = Female
- Figure 42Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller
Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly
Controlled Asthma Before and After June 2, 2010 where Sex = Male



	Table of Contents
Figure 43	Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010 where Race = Unknown
<u>Figure 44</u>	Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010 where Race = American Indian/Alaska Native
<u>Figure 45</u>	Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010 where Race = Asian
<u>Figure 46</u>	Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010 where Race = Black/African American
Figure 47	Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010 where Race = Native Hawaiian/Other Pacific Islander
<u>Figure 48</u>	Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010 where Race = White
<u>Appendix A</u>	Start and End Dates for Each Data Partner (DP) up to Request Distribution Date (April 6, 2020)
<u>Appendix B</u>	List of Generic and Brand Names of Medical Products Used to Define Single Ingredient (SI) and Fixed Dose Combination (FDC) Long-Acting Beta-2 Agonist (LABA)s and Other non-LABA Asthma Controller Medication (ACM) in this Request
<u>Appendix C</u>	List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) Diagnosis Codes Used to Define Inclusion and Exclusion Criteria in this Request
<u>Appendix D</u>	List of Generic and Brand Names of Medical Products Used to Define Poorly Controlled Asthma in this Request
<u>Appendix E</u>	Specifications Defining Parameters for this Request



Glossary of Terms for Analyses Using Cohort Identification and Descriptive Analysis (CIDA) Module*

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing. **Blackout Period** - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time." **Exposure Extension Period** - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.



Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode. Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report



Table 1a. Parameter Estimates from the Segmented Regression Model of Monthly Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹

	Beta Estimate	95% Confidence Interval	Approximate P-Value
Initial Model Parameters (df = 103) ²			
Intercept	0.013269	(0.011697, 0.014842)	<.001
Baseline trend	0.000038	(-0.000024, 0.000100)	0.227
Level Change (After Intervention 1)	-0.002089	(-0.003911, -0.000267)	0.025
Trend Change (After Intervention 1)	-0.000054	(-0.000128, 0.000020)	0.151
Most Parsimonious Final Model Paramete	ers (df = 105) ^{2,3}		
Intercept	0.014090	(0.013241, 0.014939)	<.001
Level Change (After Intervention 1)	-0.001852	(-0.002929, -0.000775)	<.001

¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model. An anticipatory period starting from February 2, 2010 (rounded to the nearest subsequent month) up to the month prior to the intervention was implemented.

²df = degrees of freedom. Maximum likelihood estimation method is used to obtain the estimates here. Maximum likelihood estimation method adjusts for autocorrelation. The p-value is calculated under the assumption of asymptotic normality.



Table 1b. Parameter Estimates from the Segmented Regression Model of Monthly Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹, by Age Group

	Beta Estimate	95% Confidence Interval	Approximate P-Value
Initial Model Parameters			
Age Group (Years)			
18-45 (df = 103) ²			
Intercept	0.013447	(0.011895, 0.014999)	<.001
Baseline trend	0.000021	(-0.000040, 0.000083)	0.491
Level Change (After Intervention 1)	-0.001978	(-0.003804, -0.000153)	0.034
Trend Change (After Intervention 1)	-0.000049	(-0.000122, 0.000023)	0.180
46-64 (df = 103) ²			
Intercept	0.014294	(0.012617, 0.015971)	<.001
Baseline trend	0.000055	(-0.000011, 0.000122)	0.100
Level Change (After Intervention 1)	-0.002601	(-0.004569, -0.000633)	0.010
Trend Change (After Intervention 1)	-0.000070	(-0.000149, 0.000009)	0.080
65+ (df = 103) ²			
Intercept	0.009492	(0.007562, 0.011422)	<.001
Baseline trend	0.000051	(-0.000024, 0.000126)	0.181
Level Change (After Intervention 1)	-0.000618	(-0.002767, 0.001530)	0.569
Trend Change (After Intervention 1)	-0.000035	(-0.000126, 0.000057)	0.450
Most Parsimonious Final Model Parameter	s ³		
Age Group (Years)			
18-45 (df = 105) ²			
Intercept	0.013881	(0.013039, 0.014723)	<.001
Level Change (After Intervention 1)	-0.002417	(-0.003489, -0.001346)	<.001
46-64 (df = 105) ²			
Intercept	0.015508	(0.014578, 0.016438)	<.001
Level Change (After Intervention 1)	-0.001988	(-0.003169, -0.000808)	0.001
65+ (df = 106) ²			
Intercept	0.011135	(0.010305, 0.011965)	<.001

¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model. An anticipatory period starting from February 2, 2010 (rounded to the nearest subsequent month) up to the month prior to the intervention was implemented.

²df = degrees of freedom. Maximum likelihood estimation method is used to obtain the estimates here. Maximum likelihood estimation method adjusts for autocorrelation. The p-value is calculated under the assumption of asymptotic normality.



Table 1c. Parameter Estimates from the Segmented Regression Model of Monthly Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹, by Sex

	Beta Estimate	95% Confidence Interval	Approximate P-Value
Initial Model Parameters			
Sex			
Female (df = 103) ²			
Intercept	0.013107	(0.011574, 0.014639)	<.001
Baseline trend	0.000041	(-0.000020, 0.000101)	0.186
Level Change (After Intervention 1)	-0.001966	(-0.003766, -0.000166)	0.033
Trend Change (After Intervention 1)	-0.000057	(-0.000129, 0.000015)	0.117
Male (df = 103) ²			
Intercept	0.013606	(0.011952, 0.015260)	<.001
Baseline trend	0.000033	(-0.000032, 0.000098)	0.321
Level Change (After Intervention 1)	-0.002393	(-0.004311, -0.000474)	0.015
Trend Change (After Intervention 1)	-0.000047	(-0.000125, 0.000030)	0.231
Most Parsimonious Final Model Parameter	s ³		
Sex			
Female (df = 105) ²			
Intercept	0.013987	(0.013154, 0.014820)	<.001
Level Change (After Intervention 1)	-0.001690	(-0.002749, -0.000632)	0.002
Male (df = 105) ²			
Intercept	0.014311	(0.013438, 0.015185)	<.001
Level Change (After Intervention 1)	-0.002209	(-0.003318, -0.001100)	<.001

¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model. An anticipatory period starting from February 2, 2010 (rounded to the nearest subsequent month) up to the month prior to the intervention was implemented.

²df = degrees of freedom. Maximum likelihood estimation method is used to obtain the estimates here. Maximum likelihood estimation method adjusts for autocorrelation. The p-value is calculated under the assumption of asymptotic normality.



Table 1d. Parameter Estimates from the Segmented Regression Model of Monthly Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹, by Race

	Beta Estimate	95% Confidence Interval	Approximate P-Value
Initial Model Parameters			
Race			
Unknown (df = 103) ²			
Intercept	0.016773	(0.015006, 0.018540)	<.001
Baseline Trend	-0.000000	(-0.000070, 0.000070)	0.989
Level Change (After Intervention 1)	-0.002478	(-0.004563, -0.000392)	0.020
Trend Change (After Intervention 1)	-0.000015	(-0.000098, 0.000068)	0.716
American Indian/Alaska Native (df = 103) ²			
Intercept	0.008224	(0.006375, 0.010073)	<.001
Baseline Trend	0.000077	(0.000002, 0.000152)	0.045
Level Change (After Intervention 1)	-0.001776	(-0.004128, 0.000576)	0.137
Trend Change (After Intervention 1)	-0.000061	(-0.000145, 0.000024)	0.158
Asian (df = 103) ²			
Intercept	0.008691	(0.006718, 0.010664)	<.001
Baseline Trend	0.000036	(-0.000043, 0.000115)	0.373
Level Change (After Intervention 1)	0.001218	(-0.001201, 0.003637)	0.320
Trend Change (After Intervention 1)	-0.000031	(-0.000123, 0.000061)	0.506
Black/African American (df = 103) ²			
Intercept	0.009600	(0.007676, 0.011524)	<.001
Baseline Trend	0.000032	(-0.000043, 0.000107)	0.396
Level Change (After Intervention 1)	0.000006	(-0.002110, 0.002122)	0.996
Trend Change (After Intervention 1)	-0.000022	(-0.000113, 0.000069)	0.627
Native Hawaiian/Other Pacific Islander (df	= 103) ³		
Intercept	0.009522	(0.007641, 0.011403)	<.001
Baseline Trend	0.000001	(-0.000075 <i>,</i> 0.000078)	0.969
Level Change (After Intervention 1)	-0.001470	(-0.003842, 0.000902)	0.222
Trend Change (After Intervention 1)	-0.000008	(-0.000094, 0.000079)	0.863
White (df = 103) ²			
Intercept	0.009366	(0.007879, 0.010852)	<.001
Baseline Trend	0.000073	(0.000014, 0.000132)	0.015
Level Change (After Intervention 1)	-0.001013	(-0.002743, 0.000718)	0.248
Trend Change (After Intervention 1)	-0.000077	(-0.000146, -0.000007)	0.032
Most Parsimonious Final Model Parameter	s ⁴		
Race			
Unknown (df = 105) ²			
Intercept	0.016746	(0.015846, 0.017647)	<.001
Level Change (After Intervention 1)	-0.002968	(-0.004117, -0.001820)	<.001
American Indian/Alaska Native (df = 106) ³			
Intercept	0.010071	(0.009384, 0.010759)	<.001



Table 1d. Parameter Estimates from the Segmented Regression Model of Monthly Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹, by Race

	Beta Estimate	95% Confidence Interval	Approximate P-Value
Most Parsimonious Final Model Parameter	rs ⁴		
Race			
Asian (df = 105) ²			
Intercept	0.009463	(0.008487, 0.010439)	<.001
Level Change (After Intervention 1)	0.002090	(0.000836, 0.003343)	0.001
Black/African American (df = 106) ²			
Intercept	0.010862	(0.010129, 0.011595)	<.001
Native Hawaiian/Other Pacific Islander (df	= 105) ³		
Intercept	0.009554	(0.008639, 0.010469)	<.001
Level Change (After Intervention 1)	-0.001633	(-0.002814, -0.000451)	0.007
White (df = 106) ²			
Intercept	0.011132	(0.010545, 0.011719)	<.001

¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model. An anticipatory period starting from February 2, 2010 (rounded to the nearest subsequent month) up to the month prior to the intervention was implemented.

²df = degrees of freedom. Maximum likelihood estimation method is used to obtain the estimates here. Maximum likelihood estimation method adjusts for autocorrelation. The p-value is calculated under the assumption of asymptotic normality.

³Ordinary least squares method is used to obtain the estimates here. The p-value is calculated under the assumption of asymptotic normality. ⁴Most parsimonious final model parameters were selected from initial model parameters using backwards selection with a cutoff of 0.05 Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete



Table 1e. Parameter Estimates from the Segmented Regression Model of Monthly Proportion of Incident Long-Acting Beta-2Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-DoseCombination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel DistributedDatabase (SDD) after June 2, 20101

	Beta Estimate	95% Confidence Interval	Approximate P-Value
Initial Model Parameters (df = 103) ²			
Intercept	0.012859	(0.011295, 0.014422)	<.001
Baseline Trend	0.000047	(-0.000015, 0.000108)	0.134
Level Change (After Intervention 1)	-0.002104	(-0.003913, -0.000294)	0.023
Trend Change (After Intervention 1)	-0.000062	(-0.000136, 0.000011)	0.097
Most Parsimonious Final Model Paramet	ers (df = 105) ^{2,3}		
Intercept	0.013880	(0.013017, 0.014743)	<.001
Level Change (After Intervention 1)	-0.001683	(-0.002775, -0.000590)	0.003

¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model. An anticipatory period starting from February 2, 2010 (rounded to the nearest subsequent month) up to the month prior to the intervention was implemented.

²df = degrees of freedom. Maximum likelihood estimation method is used to obtain the estimates here. Maximum likelihood estimation method adjusts for autocorrelation. The p-value is calculated under the assumption of asymptotic normality.



Table 1f. Parameter Estimates from the Segmented Regression Model of Monthly Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹, by Age Group

	Beta Estimate	95% Confidence Interval	Approximate P-Value
Initial Model Parameters			
Age Group (Years)			
18-45 (df = 103) ²			
Intercept	0.013142	(0.011599, 0.014686)	<.001
Baseline Trend	0.000028	(-0.000033, 0.000089)	0.363
Level Change (After Intervention 1)	-0.001997	(-0.003808, -0.000187)	0.031
Trend Change (After Intervention 1)	-0.000056	(-0.000128, 0.000017)	0.130
46-64 (df = 103) ²			
Intercept	0.013771	(0.012107, 0.015435)	<.001
Baseline Trend	0.000067	(0.000001, 0.000133)	0.046
Level Change (After Intervention 1)	-0.002623	(-0.004577, -0.000669)	0.009
Trend Change (After Intervention 1)	-0.000081	(-0.000159, -0.000003)	0.043
65+ (df = 103) ²			
Intercept	0.009023	(0.007104, 0.010942)	<.001
Baseline Trend	0.000060	(-0.000014, 0.000135)	0.113
Level Change (After Intervention 1)	-0.000594	(-0.002737, 0.001550)	0.584
Trend Change (After Intervention 1)	-0.000044	(-0.000134, 0.000047)	0.344
Most Parsimonious Final Model Parameter	s ³		
Age Group (Years)			
18-45 (df = 105) ²			
Intercept	0.013723	(0.012877, 0.014570)	<.001
Level Change (After Intervention 1)	-0.002290	(-0.003365, -0.001216)	<.001
46-64 (df = 103) ²			
Intercept	0.013771	(0.012107, 0.015435)	<.001
Baseline Trend	0.000067	(0.000001, 0.000133)	0.046
Level Change (After Intervention 1)	-0.002623	(-0.004577, -0.000669)	0.009
Trend Change (After Intervention 1)	-0.000081	(-0.000159, -0.000003)	0.043
65+ (df = 105) ²			
Intercept	0.009756	(0.008421, 0.011090)	<.001
Baseline Trend	0.000024	(0.000002, 0.000045)	0.033

¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model. An anticipatory period starting from February 2, 2010 (rounded to the nearest subsequent month) up to the month prior to the intervention was implemented.

²df = degrees of freedom. Maximum likelihood estimation method is used to obtain the estimates here. Maximum likelihood estimation method adjusts for autocorrelation. The p-value is calculated under the assumption of asymptotic normality.



Table 1g. Parameter Estimates from the Segmented Regression Model of Monthly Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹, by Sex

	Beta Estimate	95% Confidence Interval	Approximate P-Value
Initial Model Parameters			
Sex			
Female (df = 103) ²			
Intercept	0.012688	(0.011169, 0.014207)	<.001
Baseline Trend	0.000050	(-0.000010, 0.000110)	0.103
Level Change (After Intervention 1)	-0.001982	(-0.003764, -0.000200)	0.030
Trend Change (After Intervention 1)	-0.000066	(-0.000137, 0.000006)	0.071
Male (df = 103) ²			
Intercept	0.013216	(0.011556, 0.014876)	<.001
Baseline Trend	0.000041	(-0.000024, 0.000106)	0.215
Level Change (After Intervention 1)	-0.002410	(-0.004330, -0.000490)	0.014
Trend Change (After Intervention 1)	-0.000055	(-0.000133, 0.000023)	0.166
Most Parsimonious Final Model Parameter	s ³		
Sex			
Female (df = 105) ²			
Intercept	0.013772	(0.012930, 0.014614)	<.001
Level Change (After Intervention 1)	-0.001515	(-0.002584, -0.000446)	0.006
Male (df = 105) ²			
Intercept	0.014110	(0.013219, 0.015001)	<.001
Level Change (After Intervention 1)	-0.002045	(-0.003174, -0.000916)	<.001

¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model. An anticipatory period starting from February 2, 2010 (rounded to the nearest subsequent month) up to the month prior to the intervention was implemented.

²df = degrees of freedom. Maximum likelihood estimation method is used to obtain the estimates here. Maximum likelihood estimation method adjusts for autocorrelation. The p-value is calculated under the assumption of asymptotic normality.



Table 1h. Parameter Estimates from the Segmented Regression Model of Monthly Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹, by Race

	Beta Estimate	95% Confidence Interval	Approximate P-Value
Initial Model Parameters			
Race			
Unknown (df = 103) ²			
Intercept	0.016558	(0.014796, 0.018320)	<.001
Baseline Trend	0.000004	(-0.000066, 0.000074)	0.907
Level Change (After Intervention 1)	-0.002495	(-0.004573, -0.000416)	0.019
Trend Change (After Intervention 1)	-0.000019	(-0.000102, 0.000063)	0.643
American Indian/Alaska Native (df = 103) ³			
Intercept	0.007940	(0.005739, 0.010141)	<.001
Baseline Trend	0.000080	(-0.000010, 0.000169)	0.080
Level Change (After Intervention 1)	-0.001726	(-0.004501, 0.001049)	0.220
Trend Change (After Intervention 1)	-0.000061	(-0.000163, 0.000040)	0.233
Asian (df = 103) ²			
Intercept	0.007986	(0.006025, 0.009947)	<.001
Baseline Trend	0.000051	(-0.000027, 0.000130)	0.199
Level Change (After Intervention 1)	0.001177	(-0.001224, 0.003577)	0.333
Trend Change (After Intervention 1)	-0.000045	(-0.000136, 0.000046)	0.329
Black/African American (df = 103) ²			
Intercept	0.009081	(0.007178, 0.010984)	<.001
Baseline Trend	0.000043	(-0.000031, 0.000117)	0.251
Level Change (After Intervention 1)	0.000011	(-0.002103, 0.002126)	0.992
Trend Change (After Intervention 1)	-0.000033	(-0.000122, 0.000057)	0.475
Native Hawaiian/Other Pacific Islander (df	= 103) ³		
Intercept	0.009102	(0.007182, 0.011021)	<.001
Baseline Trend	0.000008	(-0.000070 <i>,</i> 0.000086)	0.836
Level Change (After Intervention 1)	-0.001344	(-0.003764, 0.001076)	0.273
Trend Change (After Intervention 1)	-0.000015	(-0.000103, 0.000074)	0.739
White (df = 103) ²			
Intercept	0.008708	(0.007221, 0.010195)	<.001
Baseline Trend	0.000087	(0.000028, 0.000145)	0.004
Level Change (After Intervention 1)	-0.001002	(-0.002724, 0.000721)	0.252
Trend Change (After Intervention 1)	-0.000090	(-0.000160, -0.000020)	0.012
Most Parsimonious Final Model Parameter	s ⁴		
Race			
Unknown (df = 105)2			
Intercept	0.016632	(0.015734, 0.017530)	<.001
Level Change (After Intervention 1)	-0.002881	(-0.004026, -0.001736)	<.001
American Indian/Alaska Native (df = 106) ³			
Intercept	0.009939	(0.009252, 0.010627)	<.001



Table 1h. Parameter Estimates from the Segmented Regression Model of Monthly Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹, by Race

	Beta Estimate	95% Confidence Interval	Approximate P-Value
Most Parsimonious Final Model Parameters	5 ⁴		
Race			
Asian (df = 105) ²			
Intercept	0.008546	(0.007195, 0.009897)	<.001
Baseline Trend	0.000038	(0.000015, 0.000060)	0.001
Black/African American (df = 105) ²			
Intercept	0.009574	(0.008281, 0.010867)	<.001
Baseline Trend	0.000022	(0.000001, 0.000043)	0.042
Native Hawaiian/Other Pacific Islander (df =	= 105) ³		
Intercept	0.009276	(0.008342, 0.010210)	<.001
Level Change (After Intervention 1)	-0.001394	(-0.002599, -0.000188)	0.024
White (df = 104) ²			
Intercept	0.008995	(0.007542, 0.010447)	<.001
Baseline Trend	0.000066	(0.000018, 0.000114)	0.008
Trend Change (After Intervention 1)	-0.000079	(-0.000148, -0.000009)	0.027

¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model. An anticipatory period starting from February 2, 2010 (rounded to the nearest subsequent month) up to the month prior to the intervention was implemented.

²df = degrees of freedom. Maximum likelihood estimation method is used to obtain the estimates here. Maximum likelihood estimation method adjusts for autocorrelation. The p-value is calculated under the assumption of asymptotic normality.

³Ordinary least squares method is used to obtain the estimates here. The p-value is calculated under the assumption of asymptotic normality. ⁴Most parsimonious final model parameters were selected from initial model parameters using backwards selection with a cutoff of 0.05 Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete



Table 1i. Parameter Estimates from the Segmented Regression Model of Monthly Proportion of Incident Long-Acting Beta-2Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-DoseCombination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel DistributedDatabase (SDD) after June 2, 2010¹

	Beta Estimate	95% Confidence Interval	Approximate P-Value
Initial Model Parameters (df = 103) ²			
Intercept	0.012510	(0.010952, 0.014069)	<.001
Baseline Trend	0.000055	(-0.000007, 0.000116)	0.080
Level Change (After Intervention 1)	-0.002128	(-0.003926, -0.000330)	0.021
Trend Change (After Intervention 1)	-0.000069	(-0.000143, 0.000004)	0.064
Most Parsimonious Final Model Paramet	ers (df = 105) ^{2,3}		
Intercept	0.013707	(0.012833, 0.014581)	<.001
Level Change (After Intervention 1)	-0.001547	(-0.002652, -0.000441)	0.007

¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model. An anticipatory period starting from February 2, 2010 (rounded to the nearest subsequent month) up to the month prior to the intervention was implemented.

²df = degrees of freedom. Maximum likelihood estimation method is used to obtain the estimates here. Maximum likelihood estimation method adjusts for autocorrelation. The p-value is calculated under the assumption of asymptotic normality.



Table 1j. Parameter Estimates from the Segmented Regression Model of Monthly Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹, by Age Group

	Beta Estimate	95% Confidence Interval	Approximate P-Value
Initial Model Parameters			
Age Group (Years)			
18-45 (df = 105) ²			
Intercept	0.012872	(0.011334, 0.014409)	<.001
Baseline Trend	0.000034	(-0.000026, 0.000095)	0.263
Level Change (After Intervention 1)	-0.002025	(-0.003830, -0.000221)	0.028
Trend Change (After Intervention 1)	-0.000062	(-0.000134, 0.000011)	0.093
46-64 (df = 103) ²			
Intercept	0.013349	(0.011709, 0.014989)	<.001
Baseline Trend	0.000076	(0.000011, 0.000141)	0.023
Level Change (After Intervention 1)	-0.002633	(-0.004558, -0.000709)	0.008
Trend Change (After Intervention 1)	-0.000089	(-0.000166, -0.000012)	0.024
65+ (df = 103) ²			
Intercept	0.008599	(0.006688, 0.010510)	<.001
Baseline Trend	0.000071	(-0.000004, 0.000145)	0.063
Level Change (After Intervention 1)	-0.000658	(-0.002787, 0.001471)	0.542
Trend Change (After Intervention 1)	-0.000053	(-0.000144, 0.000038)	0.249
Most Parsimonious Final Model Parameter	s ³		
Age Group (Years)			
18-45 (df = 105) ²			
Intercept	0.013593	(0.012743, 0.014444)	<.001
Level Change (After Intervention 1)	-0.002184	(-0.003264, -0.001103)	<.001
46-64 (df = 103) ²			
Intercept	0.013349	(0.011709, 0.014989)	<.001
Baseline Trend	0.000076	(0.000011, 0.000141)	0.023
Level Change (After Intervention 1)	-0.002633	(-0.004558, -0.000709)	0.008
Trend Change (After Intervention 1)	-0.000089	(-0.000166, -0.000012)	0.024
65+ (df = 105) ²			
Intercept	0.009485	(0.008127, 0.010842)	<.001
Baseline Trend	0.000027	(0.000005, 0.000049)	0.018

¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model. An anticipatory period starting from February 2, 2010 (rounded to the nearest subsequent month) up to the month prior to the intervention was implemented.

²df = degrees of freedom. Maximum likelihood estimation method is used to obtain the estimates here. Maximum likelihood estimation method adjusts for autocorrelation. The p-value is calculated under the assumption of asymptotic normality.



Table 1k. Parameter Estimates from the Segmented Regression Model of Monthly Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹, by Sex

	Beta Estimate	95% Confidence Interval	Approximate P-Value
Initial Model Parameters			
Sex			
Female (df = 105) ²			
Intercept	0.012342	(0.010828, 0.013855)	<.001
Baseline Trend	0.000058	(-0.000002, 0.000117)	0.059
Level Change (After Intervention 1)	-0.002007	(-0.003779, -0.000236)	0.027
Trend Change (After Intervention 1)	-0.000073	(-0.000144, -0.000002)	0.045
Male (df = 103) ²			
Intercept	0.012865	(0.011207, 0.014523)	<.001
Baseline Trend	0.000049	(-0.000016, 0.000114)	0.140
Level Change (After Intervention 1)	-0.002431	(-0.004342, -0.000521)	0.013
Trend Change (After Intervention 1)	-0.000062	(-0.000140, 0.000016)	0.118
Most Parsimonious Final Model Parameter	s ³		
Sex			
Female (df = 105) ²			
Intercept	0.013601	(0.012740, 0.014461)	<.001
Level Change (After Intervention 1)	-0.001381	(-0.002472, -0.000291)	0.014
Male (df = 105) ²			
Intercept	0.013934	(0.013027, 0.014840)	<.001
Level Change (After Intervention 1)	-0.001907	(-0.003054, -0.000760)	0.001

¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model. An anticipatory period starting from February 2, 2010 (rounded to the nearest subsequent month) up to the month prior to the intervention was implemented.

²df = degrees of freedom. Maximum likelihood estimation method is used to obtain the estimates here. Maximum likelihood estimation method adjusts for autocorrelation. The p-value is calculated under the assumption of asymptotic normality.



Table 11. Parameter Estimates from the Segmented Regression Model of Monthly Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹, by Race

	Beta Estimate	95% Confidence Interval	Approximate P-Value
Initial Model Parameters			
Race			
Unknown (df = 103) ²			
Intercept	0.016361	(0.014610, 0.018112)	<.001
Baseline Trend	0.00008	(-0.000061, 0.000078)	0.811
Level Change (After Intervention 1)	-0.002508	(-0.004573, -0.000443)	0.018
Trend Change (After Intervention 1)	-0.000023	(-0.000105, 0.000059)	0.574
American Indian/Alaska Native (df = 103) ³			
Intercept	0.007508	(0.005329, 0.009687)	<.001
Baseline Trend	0.000089	(0.000001, 0.000177)	0.049
Level Change (After Intervention 1)	-0.001808	(-0.004555, 0.000940)	0.195
Trend Change (After Intervention 1)	-0.000068	(-0.000169, 0.000032)	0.182
Asian (df = 103) ²			
Intercept	0.007558	(0.005590, 0.009526)	<.001
Baseline Trend	0.000061	(-0.000018, 0.000140)	0.130
Level Change (After Intervention 1)	0.001118	(-0.001289, 0.003525)	0.359
Trend Change (After Intervention 1)	-0.000053	(-0.000145, 0.000039)	0.254
Black/African American (df = 103) ²			
Intercept	0.008574	(0.006631, 0.010516)	<.001
Baseline Trend	0.000056	(-0.000020, 0.000131)	0.146
Level Change (After Intervention 1)	-0.000060	(-0.002188, 0.002069)	0.956
Trend Change (After Intervention 1)	-0.000044	(-0.000136, 0.000047)	0.340
Native Hawaiian/Other Pacific Islander (df	= 103) ³		
Intercept	0.008880	(0.006952, 0.010809)	<.001
Baseline Trend	0.000011	(-0.000067, 0.000089)	0.778
Level Change (After Intervention 1)	-0.001249	(-0.003681, 0.001183)	0.311
Trend Change (After Intervention 1)	-0.000018	(-0.000107, 0.000071)	0.691
White (df = 103) ²			
Intercept	0.008155	(0.006657, 0.009654)	<.001
Baseline Trend	0.000099	(0.000040, 0.000158)	0.001
Level Change (After Intervention 1)	-0.001028	(-0.002750, 0.000693)	0.239
Trend Change (After Intervention 1)	-0.000101	(-0.000171, -0.000030)	0.006
Most Parsimonious Final Model Parameters	5 ⁴		
Race			
Unknown (df = 105) ²			
Intercept	0.016528	(0.015635, 0.017422)	<.001
Level Change (After Intervention 1)	-0.002801	(-0.003940, -0.001661)	<.001
American Indian/Alaska Native (df = 106) ³			
Intercept	0.009821	(0.009136, 0.010506)	<.001



Table 11. Parameter Estimates from the Segmented Regression Model of Monthly Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹, by Race

	Beta Estimate	95% Confidence Interval	Approximate P-Value
Most Parsimonious Final Model Parameters	5 ⁴		
Race			
Asian (df = 105) ²			
Intercept	0.008244	(0.006876, 0.009611)	<.001
Baseline Trend	0.000041	(0.000019, 0.000063)	<.001
Black/African American (df = 105) ²			
Intercept	0.009254	(0.007921, 0.010587)	<.001
Baseline Trend	0.000026	(0.000004, 0.000047)	0.021
Native Hawaiian/Other Pacific Islander (df :	= 105) ³		
Intercept	0.009120	(0.008181, 0.010058)	<.001
Level Change (After Intervention 1)	-0.001237	(-0.002449, -0.000026)	0.045
White (df = 104) ²			
Intercept	0.008447	(0.006980, 0.009913)	<.001
Baseline Trend	0.000078	(0.000029, 0.000127)	0.002
Trend Change (After Intervention 1)	-0.000090	(-0.000160, -0.000019)	0.013

¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model. An anticipatory period starting from February 2, 2010 (rounded to the nearest subsequent month) up to the month prior to the intervention was implemented.

²df = degrees of freedom. Maximum likelihood estimation method is used to obtain the estimates here. Maximum likelihood estimation method adjusts for autocorrelation. The p-value is calculated under the assumption of asymptotic normality.

³Ordinary least squares method is used to obtain the estimates here. The p-value is calculated under the assumption of asymptotic normality. ⁴Most parsimonious final model parameters were selected from initial model parameters using backwards selection with a cutoff of 0.05 Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete



Table 1m. Parameter Estimates from the Segmented Regression Model of Monthly Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹

	Beta Estimate	95% Confidence Interval	Approximate P-Value
Initial Model Parameters (df = 103) ²			
Intercept	0.013060	(0.011490, 0.014631)	<.001
Baseline Trend	0.000042	(-0.000020, 0.000104)	0.178
Level Change (After Intervention 1)	-0.002101	(-0.003918, -0.000284)	0.024
Trend Change (After Intervention 1)	-0.000058	(-0.000132, 0.000016)	0.125
Most Parsimonious Final Model Paramet	ers (df = 105) ^{2,3}		
Intercept	0.013979	(0.013123, 0.014834)	<.001
Level Change (After Intervention 1)	-0.001766	(-0.002850, -0.000683)	0.002

¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model. An anticipatory period starting from February 2, 2010 (rounded to the nearest subsequent month) up to the month prior to the intervention was implemented.

²df = degrees of freedom. Maximum likelihood estimation method is used to obtain the estimates here. Maximum likelihood estimation method adjusts for autocorrelation. The p-value is calculated under the assumption of asymptotic normality.



Table 1n. Parameter Estimates from the Segmented Regression Model of Monthly Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹, by Age Group

	Beta Estimate	95% Confidence Interval	Approximate P-Value
Initial Model Parameters			
Age Group (Years)			
18-45 (df = 105) ²			
Intercept	0.013319	(0.011773, 0.014866)	<.001
Baseline Trend	0.000024	(-0.000037, 0.000085)	0.440
Level Change (After Intervention 1)	-0.001986	(-0.003805, -0.000167)	0.033
Trend Change (After Intervention 1)	-0.000052	(-0.000124, 0.000021)	0.161
46-64 (df = 103) ²			
Intercept	0.014024	(0.012357, 0.015691)	<.001
Baseline Trend	0.000061	(-0.000005, 0.000127)	0.070
Level Change (After Intervention 1)	-0.002596	(-0.004551, -0.000641)	0.010
Trend Change (After Intervention 1)	-0.000075	(-0.000153, 0.000004)	0.061
65+ (df = 103) ²			
Intercept	0.009186	(0.007237, 0.011136)	<.001
Baseline Trend	0.000058	(-0.000017, 0.000134)	0.129
Level Change (After Intervention 1)	-0.000693	(-0.002852, 0.001465)	0.525
Trend Change (After Intervention 1)	-0.000041	(-0.000134, 0.000051)	0.377
Most Parsimonious Final Model Parameter	'S ³		
Age Group (Years)			
18-45 (df = 105) ²			
Intercept	0.013810	(0.012968, 0.014652)	<.001
Level Change (After Intervention 1)	-0.002363	(-0.003433, -0.001293)	<.001
46-64 (df = 105) ²			
Intercept	0.015357	(0.014421, 0.016293)	<.001
Level Change (After Intervention 1)	-0.001866	(-0.003054, -0.000678)	0.002
65+ (df = 105) ²			
Intercept	0.009892	(0.008545, 0.011238)	<.001
Baseline Trend	0.000022	(0.000000, 0.000044)	0.049

¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model. An anticipatory period starting from February 2, 2010 (rounded to the nearest subsequent month) up to the month prior to the intervention was implemented.

²df = degrees of freedom. Maximum likelihood estimation method is used to obtain the estimates here. Maximum likelihood estimation method adjusts for autocorrelation. The p-value is calculated under the assumption of asymptotic normality.



Table 1o. Parameter Estimates from the Segmented Regression Model of Monthly Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹, by Sex

	Beta Estimate	95% Confidence Interval	Approximate P-Value
Initial Model Parameters			
Sex			
Female (df = 105) ²			
Intercept	0.012907	(0.011374, 0.014440)	<.001
Baseline Trend	0.000045	(-0.000016, 0.000105)	0.146
Level Change (After Intervention 1)	-0.001969	(-0.003766, -0.000172)	0.032
Trend Change (After Intervention 1)	-0.000061	(-0.000133, 0.000011)	0.097
Male (df = 103) ²			
Intercept	0.013378	(0.011731, 0.015025)	<.001
Baseline Trend	0.000038	(-0.000027, 0.000103)	0.252
Level Change (After Intervention 1)	-0.002423	(-0.004332, -0.000514)	0.013
Trend Change (After Intervention 1)	-0.000051	(-0.000129, 0.000026)	0.192
Most Parsimonious Final Model Parameter	s ³		
Sex			
Female (df = 105) ²			
Intercept	0.013876	(0.013039, 0.014714)	<.001
Level Change (After Intervention 1)	-0.001603	(-0.002667, -0.000540)	0.004
Male (df = 105) ²			
Intercept	0.014194	(0.013318, 0.015071)	<.001
Level Change (After Intervention 1)	-0.002120	(-0.003232, -0.001008)	<.001

¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model. An anticipatory period starting from February 2, 2010 (rounded to the nearest subsequent month) up to the month prior to the intervention was implemented.

²df = degrees of freedom. Maximum likelihood estimation method is used to obtain the estimates here. Maximum likelihood estimation method adjusts for autocorrelation. The p-value is calculated under the assumption of asymptotic normality.



Table 1p. Parameter Estimates from the Segmented Regression Model of Monthly Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹, by Race

	Beta Estimate	95% Confidence Interval	Approximate P-Value	
Initial Model Parameters				
Race				
Unknown (df = 103) ²				
Intercept	0.016646	(0.014884, 0.018409)	<.001	
Baseline Trend	0.000002	(-0.000068, 0.000072)	0.950	
Level Change (After Intervention 1)	-0.002492	(-0.004571, -0.000412)	0.019	
Trend Change (After Intervention 1)	-0.000018	(-0.000100, 0.000065)	0.674	
American Indian/Alaska Native (df = 103) ³				
Intercept	0.008142	(0.005992, 0.010291)	<.001	
Baseline Trend	0.000073	(-0.000014, 0.000160)	0.100	
Level Change (After Intervention 1)	-0.001668	(-0.004379, 0.001042)	0.225	
Trend Change (After Intervention 1)	-0.000054	(-0.000153, 0.000045)	0.280	
Asian (df = 103) ²				
Intercept	0.008377	(0.006389, 0.010366)	<.001	
Baseline Trend	0.000043	(-0.000037, 0.000123)	0.287	
Level Change (After Intervention 1)	0.001175	(-0.001262, 0.003613)	0.341	
Trend Change (After Intervention 1)	-0.000038	(-0.000130, 0.000055)	0.422	
Black/African American (df = 103) ²				
Intercept	0.009500	(0.007580, 0.011421)	<.001	
Baseline Trend	0.000031	(-0.000043, 0.000106)	0.408	
Level Change (After Intervention 1)	0.000126	(-0.001987, 0.002238)	0.906	
Trend Change (After Intervention 1)	-0.000021	(-0.000112, 0.000069)	0.641	
Native Hawaiian/Other Pacific Islander (df =	= 103) ³			
Intercept	0.009513	(0.007611, 0.011416)	<.001	
Baseline Trend	-0.000002	(-0.000079, 0.000075)	0.959	
Level Change (After Intervention 1)	-0.001286	(-0.003686, 0.001113)	0.290	
Trend Change (After Intervention 1)	-0.000006	(-0.000094, 0.000082)	0.897	
White $(df = 103)^2$				
Intercept	0.009013	(0.007519, 0.010508)	<.001	
Baseline Trend	0.000081	(0.000022, 0.000139)	0.008	
Level Change (After Intervention 1)	-0.001036	(-0.002766, 0.000694)	0.238	
Trend Change (After Intervention 1)	-0.000083	(-0.000154, -0.000013)	0.021	
Most Parsimonious Final Model Parameters	4			
Race				
Unknown (df = 105) ²				
Intercept	0.016679	(0.015781, 0.017578)	<.001	
Level Change (After Intervention 1)	-0.002918	(-0.004064, -0.001773)	<.001	
American Indian/Alaska Native (df = 106) ³				
Intercept	0.009957	(0.009288, 0.010627)	<.001	



Table 1p. Parameter Estimates from the Segmented Regression Model of Monthly Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹, by Race

	Beta Estimate	95% Confidence Interval	Approximate P-Value
Most Parsimonious Final Model Parameters	s ⁴		
Race			
Asian (df = 105) ²			
Intercept	0.009308	(0.008325, 0.010292)	<.001
Level Change (After Intervention 1)	0.002219	(0.000956, 0.003483)	<.001
Black/African American (df = 106) ²			
Intercept	0.010809	(0.010051, 0.011566)	<.001
Native Hawaiian/Other Pacific Islander (df	= 105) ³		
Intercept	0.009471	(0.008545, 0.010396)	<.001
Level Change (After Intervention 1)	-0.001574	(-0.002769, -0.000379)	0.010
White $(df = 104)^2$			
Intercept	0.009308	(0.007849, 0.010766)	<.001
Baseline Trend	0.000059	(0.000011, 0.000108)	0.017
Trend Change (After Intervention 1)	-0.000072	(-0.000142, -0.000002)	0.044

¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model. An anticipatory period starting from February 2, 2010 (rounded to the nearest subsequent month) up to the month prior to the intervention was implemented.

²df = degrees of freedom. Maximum likelihood estimation method is used to obtain the estimates here. Maximum likelihood estimation method adjusts for autocorrelation. The p-value is calculated under the assumption of asymptotic normality.

³Ordinary least squares method is used to obtain the estimates here. The p-value is calculated under the assumption of asymptotic normality. ⁴Most parsimonious final model parameters were selected from initial model parameters using backwards selection with a cutoff of 0.05 Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete



Table 2a. Absolute and Relative Changes in Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹ Compared with Expected Rates Derived from Baseline Trend

			Predicted Rate	Extrapolated Rate
Outcome Measure	Beta Estimate	95% Confidence Interval	(With Intervention)	(Without Intervention)
Absolute Change at 6 Months after Intervention 1	-0.001852	(-0.002916, -0.000787)	0.012238	0.014090
Relative Change (Percent) at 6 Months after Intervention 1	-13.14	(-20.12, -6.16)	0.012238	0.014090
Absolute Change at 12 Months after Intervention 1	-0.001852	(-0.002916, -0.000787)	0.012238	0.014090
Relative Change (Percent) at 12 Months after Intervention 1	-13.14	(-20.12, -6.16)	0.012238	0.014090

¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model. An anticipatory period starting from February 2, 2010 (rounded to the nearest subsequent month) up to the month prior to the intervention was implemented.



Table 2b. Absolute and Relative Changes in Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹ Compared with Expected Rates Derived from Baseline Trend, by Age Group

			Predicted Rate	Extrapolated Rate
Outcome Measure	Beta Estimate	95% Confidence Interval	(With Intervention)	(Without Intervention)
Age Group (Years)				
18-45				
Absolute Change at 6 Months after Intervention 1	-0.002417	(-0.003478, -0.001357)	0.011464	0.013881
Relative Change (Percent) at 6 Months after Intervention 1	-17.41	(-24.29, -10.54)	0.011464	0.013881
Absolute Change at 12 Months after Intervention 1	-0.002417	(-0.003478, -0.001357)	0.011464	0.013881
Relative Change (Percent) at 12 Months after Intervention 1	-17.41	(-24.29, -10.54)	0.011464	0.013881
46-64				
Absolute Change at 6 Months after Intervention 1	-0.001988	(-0.003155, -0.000821)	0.013520	0.015508
Relative Change (Percent) at 6 Months after Intervention 1	-12.82	(-19.79, -5.85)	0.013520	0.015508
Absolute Change at 12 Months after Intervention 1	-0.001988	(-0.003155, -0.000821)	0.013520	0.015508
Relative Change (Percent) at 12 Months after Intervention 1	-12.82	(-19.79, -5.85)	0.013520	0.015508
65+				
Absolute Change at 6 Months after Intervention 1	0.000000	(0.000000, 0.000000)	0.011135	0.011135
Relative Change (Percent) at 6 Months after Intervention 1	0.00	(0.00, 0.00)	0.011135	0.011135
Absolute Change at 12 Months after Intervention 1	0.000000	(0.000000, 0.000000)	0.011135	0.011135
Relative Change (Percent) at 12 Months after Intervention 1	0.00	(0.00, 0.00)	0.011135	0.011135

¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model. An anticipatory period starting from February 2, 2010 (rounded to the nearest subsequent month) up to the month prior to the intervention was implemented.



Table 2c. Absolute and Relative Changes in Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹ Compared with Expected Rates Derived from Baseline Trend, by Sex

Outcome Measure	Beta Estimate	95% Confidence Interval	Predicted Rate (With Intervention)	Extrapolated Rate (Without Intervention)
Sex	Deta Estimate	55% confidence interval	(with intervention)	(without intervention)
Female				
Absolute Change at 6 Months after Intervention 1	-0.001690	(-0.002737, -0.000644)	0.012297	0.013987
Relative Change (Percent) at 6 Months after Intervention 1	-12.08	(-19.04, -5.13)	0.012297	0.013987
Absolute Change at 12 Months after Intervention 1	-0.001690	(-0.002737, -0.000644)	0.012297	0.013987
Relative Change (Percent) at 12 Months after Intervention 1	-12.08	(-19.04, -5.13)	0.012297	0.013987
Male				
Absolute Change at 6 Months after Intervention 1	-0.002209	(-0.003305, -0.001112)	0.012103	0.014311
Relative Change (Percent) at 6 Months after Intervention 1	-15.43	(-22.41, -8.45)	0.012103	0.014311
Absolute Change at 12 Months after Intervention 1	-0.002209	(-0.003305, -0.001112)	0.012103	0.014311
Relative Change (Percent) at 12 Months after Intervention 1	-15.43	(-22.41, -8.45)	0.012103	0.014311

¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model. An anticipatory period starting from February 2, 2010 (rounded to the nearest subsequent month) up to the month prior to the intervention was implemented.



Table 2d. Absolute and Relative Changes in Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹ Compared with Expected Rates Derived from Baseline Trend, by Race

			Predicted Rate	Extrapolated Rate
Outcome Measure	Beta Estimate	95% Confidence Interval	(With Intervention)	(Without Intervention)
Race				
Unknown				
Absolute Change at 6 Months after Intervention 1	-0.002968	(-0.004104, -0.001832)	0.013778	0.016746
Relative Change (Percent) at 6 Months after Intervention 1	-17.73	(-23.82, -11.63)	0.013778	0.016746
Absolute Change at 12 Months after Intervention 1	-0.002968	(-0.004104, -0.001832)	0.013778	0.016746
Relative Change (Percent) at 12 Months after Intervention 1	-17.73	(-23.82, -11.63)	0.013778	0.016746
American Indian/Alaska Native				
Absolute Change at 6 Months after Intervention 1	0.000000	(0.000000, 0.000000)	0.010071	0.010071
Relative Change (Percent) at 6 Months after Intervention 1	0.00	(0.00, 0.00)	0.010071	0.010071
Absolute Change at 12 Months after Intervention 1	0.000000	(0.000000, 0.000000)	0.010071	0.010071
Relative Change (Percent) at 12 Months after Intervention 1	0.00	(0.00, 0.00)	0.010071	0.010071
Asian				
Absolute Change at 6 Months after Intervention 1	0.002090	(0.000849, 0.003331)	0.011552	0.009463
Relative Change (Percent) at 6 Months after Intervention 1	22.08	(7.16, 37.00)	0.011552	0.009463
Absolute Change at 12 Months after Intervention 1	0.002090	(0.000849, 0.003331)	0.011552	0.009463
Relative Change (Percent) at 12 Months after Intervention 1	22.08	(7.16, 37.00)	0.011552	0.009463
Black/African American				
Absolute Change at 6 Months after Intervention 1	0.000000	(0.000000, 0.000000)	0.010862	0.010862
Relative Change (Percent) at 6 Months after Intervention 1	0.00	(0.00, 0.00)	0.010862	0.010862
Absolute Change at 12 Months after Intervention 1	0.000000	(0.000000, 0.000000)	0.010862	0.010862
Relative Change (Percent) at 12 Months after Intervention 1	0.00	(0.00, 0.00)	0.010862	0.010862
Native Hawaiian/Other Pacific Islander				
Absolute Change at 6 Months after Intervention 1	-0.001633	(-0.002800, -0.000465)	0.007922	0.009554
Relative Change (Percent) at 6 Months after Intervention 1	-17.09	(-28.10, -6.07)	0.007922	0.009554
Absolute Change at 12 Months after Intervention 1	-0.001633	(-0.002800, -0.000465)	0.007922	0.009554
Relative Change (Percent) at 12 Months after Intervention 1	-17.09	(-28.10, -6.07)	0.007922	0.009554
		· · · ·		



Table 2d. Absolute and Relative Changes in Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹ Compared with Expected Rates Derived from Baseline Trend, by Race

Outcome Measure Race	Beta Estimate	95% Confidence Interval	Predicted Rate (With Intervention)	Extrapolated Rate (Without Intervention)
White				
Absolute Change at 6 Months after Intervention 1	0.000000	(0.000000, 0.000000)	0.011132	0.011132
Relative Change (Percent) at 6 Months after Intervention 1	0.00	(0.00, 0.00)	0.011132	0.011132
Absolute Change at 12 Months after Intervention 1	0.000000	(0.000000, 0.000000)	0.011132	0.011132
Relative Change (Percent) at 12 Months after Intervention 1	0.00	(0.00, 0.00)	0.011132	0.011132

¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model. An anticipatory period starting from February 2, 2010 (rounded to the nearest subsequent month) up to the month prior to the intervention was implemented. Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete



Table 2e. Absolute and Relative Changes in Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹ Compared with Expected Rates Derived from Baseline Trend

			Predicted Rate	Extrapolated Rate
Outcome Measure	Beta Estimate	95% Confidence Interval	(With Intervention)	(Without Intervention)
Absolute Change at 6 Months after Intervention 1	-0.001683	(-0.002763, -0.000603)	0.012197	0.013880
Relative Change (Percent) at 6 Months after Intervention 1	-12.12	(-19.36, -4.89)	0.012197	0.013880
Absolute Change at 12 Months after Intervention 1	-0.001683	(-0.002763, -0.000603)	0.012197	0.013880
Relative Change (Percent) at 12 Months after Intervention 1	-12.12	(-19.36, -4.89)	0.012197	0.013880



Table 2f. Absolute and Relative Changes in Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹ Compared with Expected Rates Derived from Baseline Trend, by Age Group

			Predicted Rate	Extrapolated Rate
Outcome Measure	Beta Estimate	95% Confidence Interval	(With Intervention)	(Without Intervention)
Age Group (Years)				
18-45				
Absolute Change at 6 Months after Intervention 1	-0.002290	(-0.003354, -0.001227)	0.011433	0.013723
Relative Change (Percent) at 6 Months after Intervention 1	-16.69	(-23.70, -9.68)	0.011433	0.013723
Absolute Change at 12 Months after Intervention 1	-0.002290	(-0.003354, -0.001227)	0.011433	0.013723
Relative Change (Percent) at 12 Months after Intervention 1	-16.69	(-23.70, -9.68)	0.011433	0.013723
46-64				
Absolute Change at 6 Months after Intervention 1	-0.003107	(-0.005220, -0.000995)	0.013877	0.016985
Relative Change (Percent) at 6 Months after Intervention 1	-18.29	(-29.08, -7.51)	0.013877	0.016985
Absolute Change at 12 Months after Intervention 1	-0.003592	(-0.005957, -0.001227)	0.013795	0.017387
Relative Change (Percent) at 12 Months after Intervention 1	-20.66	(-31.88, -9.44)	0.013795	0.017387
65+				
Absolute Change at 6 Months after Intervention 1	0.000000	(0.000000, 0.000000)	0.010890	0.010890
Relative Change (Percent) at 6 Months after Intervention 1	0.00	(0.00, 0.00)	0.010890	0.010890
Absolute Change at 12 Months after Intervention 1	0.000000	(0.000000, 0.000000)	0.011032	0.011032
Relative Change (Percent) at 12 Months after Intervention 1	0.00	(0.00, 0.00)	0.011032	0.011032



Table 2g. Absolute and Relative Changes in Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹ Compared with Expected Rates Derived from Baseline Trend, by Sex

Outcome Measure	Beta Estimate	95% Confidence Interval	Predicted Rate (With Intervention)	Extrapolated Rate (Without Intervention)
Sex				<u> </u>
Female				
Absolute Change at 6 Months after Intervention 1	-0.001515	(-0.002572, -0.000459)	0.012256	0.013772
Relative Change (Percent) at 6 Months after Intervention 1	-11.00	(-18.18, -3.82)	0.012256	0.013772
Absolute Change at 12 Months after Intervention 1	-0.001515	(-0.002572, -0.000459)	0.012256	0.013772
Relative Change (Percent) at 12 Months after Intervention 1	-11.00	(-18.18, -3.82)	0.012256	0.013772
Male				
Absolute Change at 6 Months after Intervention 1	-0.002045	(-0.003161, -0.000929)	0.012065	0.014110
Relative Change (Percent) at 6 Months after Intervention 1	-14.49	(-21.74, -7.25)	0.012065	0.014110
Absolute Change at 12 Months after Intervention 1	-0.002045	(-0.003161, -0.000929)	0.012065	0.014110
Relative Change (Percent) at 12 Months after Intervention 1	-14.49	(-21.74, -7.25)	0.012065	0.014110



Table 2h. Absolute and Relative Changes in Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹ Compared with Expected Rates Derived from Baseline Trend, by Race

			Predicted Rate	Extrapolated Rate
Outcome Measure	Beta Estimate	95% Confidence Interval	(With Intervention)	(Without Intervention)
Race				
Unknown				
Absolute Change at 6 Months after Intervention 1	-0.002881	(-0.004014, -0.001748)	0.013751	0.016632
Relative Change (Percent) at 6 Months after Intervention 1	-17.32	(-23.46, -11.19)	0.013751	0.016632
Absolute Change at 12 Months after Intervention 1	-0.002881	(-0.004014, -0.001748)	0.013751	0.016632
Relative Change (Percent) at 12 Months after Intervention 1	-17.32	(-23.46, -11.19)	0.013751	0.016632
American Indian/Alaska Native				
Absolute Change at 6 Months after Intervention 1	0.000000	(0.000000, 0.000000)	0.009939	0.009939
Relative Change (Percent) at 6 Months after Intervention 1	0.00	(0.00, 0.00)	0.009939	0.009939
Absolute Change at 12 Months after Intervention 1	0.000000	(0.000000, 0.000000)	0.009939	0.009939
Relative Change (Percent) at 12 Months after Intervention 1	0.00	(0.00, 0.00)	0.009939	0.009939
Asian				
Absolute Change at 6 Months after Intervention 1	0.000000	(0.000000, 0.000000)	0.010346	0.010346
Relative Change (Percent) at 6 Months after Intervention 1	0.00	(0.00, 0.00)	0.010346	0.010346
Absolute Change at 12 Months after Intervention 1	0.000000	(0.000000, 0.000000)	0.010571	0.010571
Relative Change (Percent) at 12 Months after Intervention 1	0.00	(0.00, 0.00)	0.010571	0.010571
Black/African American				
Absolute Change at 6 Months after Intervention 1	0.000000	(0.000000, 0.000000)	0.010623	0.010623
Relative Change (Percent) at 6 Months after Intervention 1	0.00	(0.00, 0.00)	0.010623	0.010623
Absolute Change at 12 Months after Intervention 1	0.000000	(0.000000, 0.000000)	0.010754	0.010754
Relative Change (Percent) at 12 Months after Intervention 1	0.00	(0.00, 0.00)	0.010754	0.010754
Native Hawaiian/Other Pacific Islander				
Absolute Change at 6 Months after Intervention 1	-0.001394	(-0.002585, -0.000202)	0.007882	0.009276
Relative Change (Percent) at 6 Months after Intervention 1	-15.03	(-26.75, -3.30)	0.007882	0.009276
Absolute Change at 12 Months after Intervention 1	-0.001394	(-0.002585, -0.000202)	0.007882	0.009276
Relative Change (Percent) at 12 Months after Intervention 1	-15.03	(-26.75, -3.30)	0.007882	0.009276



Table 2h. Absolute and Relative Changes in Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹ Compared with Expected Rates Derived from Baseline Trend, by Race

Outcome Measure	Beta Estimate	95% Confidence Interval	Predicted Rate (With Intervention)	Extrapolated Rate (Without Intervention)
Race				
White				
Absolute Change at 6 Months after Intervention 1	-0.000472	(-0.000885, -0.000060)	0.011695	0.012167
Relative Change (Percent) at 6 Months after Intervention 1	-3.88	(-6.92, -0.84)	0.011695	0.012167
Absolute Change at 12 Months after Intervention 1	-0.000944	(-0.001770, -0.000119)	0.011619	0.012564
Relative Change (Percent) at 12 Months after Intervention 1	-7.52	(-13.27, -1.77)	0.011619	0.012564

¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model. An anticipatory period starting from February 2, 2010 (rounded to the nearest subsequent month) up to the month prior to the intervention was implemented. Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete



Table 2i. Absolute and Relative Changes in Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹ Compared with Expected Rates Derived from Baseline Trend

			Predicted Rate	Extrapolated Rate
Outcome Measure	Beta Estimate	95% Confidence Interval	(With Intervention)	(Without Intervention)
Absolute Change at 6 Months after Intervention 1	-0.001547	(-0.002639, -0.000454)	0.012160	0.013707
Relative Change (Percent) at 6 Months after Intervention 1	-11.28	(-18.73, -3.84)	0.012160	0.013707
Absolute Change at 12 Months after Intervention 1	-0.001547	(-0.002639, -0.000454)	0.012160	0.013707
Relative Change (Percent) at 12 Months after Intervention 1	-11.28	(-18.73, -3.84)	0.012160	0.013707



Table 2j. Absolute and Relative Changes in Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹ Compared with Expected Rates Derived from Baseline Trend, by Age Group

			Predicted Rate	Extrapolated Rate
Outcome Measure	Beta Estimate	95% Confidence Interval	(With Intervention)	(Without Intervention)
Age Group (Years)				
18-45				
Absolute Change at 6 Months after Intervention 1	-0.002184	(-0.003252, -0.001115)	0.011410	0.013593
Relative Change (Percent) at 6 Months after Intervention 1	-16.06	(-23.20, -8.93)	0.011410	0.013593
Absolute Change at 12 Months after Intervention 1	-0.002184	(-0.003252, -0.001115)	0.011410	0.013593
Relative Change (Percent) at 12 Months after Intervention 1	-16.06	(-23.20, -8.93)	0.011410	0.013593
46-64				
Absolute Change at 6 Months after Intervention 1	-0.003165	(-0.005247, -0.001083)	0.013818	0.016983
Relative Change (Percent) at 6 Months after Intervention 1	-18.64	(-29.24, -8.04)	0.013818	0.016983
Absolute Change at 12 Months after Intervention 1	-0.003697	(-0.006028, -0.001366)	0.013741	0.017438
Relative Change (Percent) at 12 Months after Intervention 1	-21.20	(-32.17, -10.23)	0.013741	0.017438
65+				
Absolute Change at 6 Months after Intervention 1	0.000000	(0.000000, 0.000000)	0.010771	0.010771
Relative Change (Percent) at 6 Months after Intervention 1	0.00	(0.00, 0.00)	0.010771	0.010771
Absolute Change at 12 Months after Intervention 1	0.000000	(0.000000, 0.000000)	0.010932	0.010932
Relative Change (Percent) at 12 Months after Intervention 1	0.00	(0.00, 0.00)	0.010932	0.010932



Table 2k. Absolute and Relative Changes in Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹ Compared with Expected Rates Derived from Baseline Trend, by Sex

Outcome Measure	Beta Estimate	95% Confidence Interval	Predicted Rate (With Intervention)	Extrapolated Rate (Without Intervention)
Sex			(,	(
Female				
Absolute Change at 6 Months after Intervention 1	-0.001381	(-0.002460, -0.000303)	0.012219	0.013601
Relative Change (Percent) at 6 Months after Intervention 1	-10.16	(-17.61, -2.70)	0.012219	0.013601
Absolute Change at 12 Months after Intervention 1	-0.001381	(-0.002460, -0.000303)	0.012219	0.013601
Relative Change (Percent) at 12 Months after Intervention 1	-10.16	(-17.61, -2.70)	0.012219	0.013601
Male				
Absolute Change at 6 Months after Intervention 1	-0.001907	(-0.003041, -0.000773)	0.012027	0.013934
Relative Change (Percent) at 6 Months after Intervention 1	-13.69	(-21.18, -6.19)	0.012027	0.013934
Absolute Change at 12 Months after Intervention 1	-0.001907	(-0.003041, -0.000773)	0.012027	0.013934
Relative Change (Percent) at 12 Months after Intervention 1	-13.69	(-21.18, -6.19)	0.012027	0.013934



Table 2I. Absolute and Relative Changes in Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹ Compared with Expected Rates Derived from Baseline Trend, by Race

			Predicted Rate	Extrapolated Rate
Outcome Measure	Beta Estimate	95% Confidence Interval	(With Intervention)	(Without Intervention)
Race				
Unknown				
Absolute Change at 6 Months after Intervention 1	-0.002801	(-0.003928, -0.001674)	0.013728	0.016528
Relative Change (Percent) at 6 Months after Intervention 1	-16.94	(-23.10, -10.79)	0.013728	0.016528
Absolute Change at 12 Months after Intervention 1	-0.002801	(-0.003928, -0.001674)	0.013728	0.016528
Relative Change (Percent) at 12 Months after Intervention 1	-16.94	(-23.10, -10.79)	0.013728	0.016528
American Indian/Alaska Native				
Absolute Change at 6 Months after Intervention 1	0.000000	(0.000000, 0.000000)	0.009821	0.009821
Relative Change (Percent) at 6 Months after Intervention 1	0.00	(0.00, 0.00)	0.009821	0.009821
Absolute Change at 12 Months after Intervention 1	0.000000	(0.000000, 0.000000)	0.009821	0.009821
Relative Change (Percent) at 12 Months after Intervention 1	0.00	(0.00, 0.00)	0.009821	0.009821
Asian				
Absolute Change at 6 Months after Intervention 1	0.000000	(0.000000, 0.000000)	0.010212	0.010212
Relative Change (Percent) at 6 Months after Intervention 1	0.00	(0.00, 0.00)	0.010212	0.010212
Absolute Change at 12 Months after Intervention 1	0.000000	(0.000000, 0.000000)	0.010459	0.010459
Relative Change (Percent) at 12 Months after Intervention 1	0.00	(0.00, 0.00)	0.010459	0.010459
Black/African American				
Absolute Change at 6 Months after Intervention 1	0.000000	(0.000000, 0.000000)	0.010487	0.010487
Relative Change (Percent) at 6 Months after Intervention 1	0.00	(0.00, 0.00)	0.010487	0.010487
Absolute Change at 12 Months after Intervention 1	0.000000	(0.000000, 0.000000)	0.010641	0.010641
Relative Change (Percent) at 12 Months after Intervention 1	0.00	(0.00, 0.00)	0.010641	0.010641
Native Hawaiian/Other Pacific Islander				
Absolute Change at 6 Months after Intervention 1	-0.001237	(-0.002435, -0.000040)	0.007882	0.009120
Relative Change (Percent) at 6 Months after Intervention 1	-13.57	(-25.66, -1.47)	0.007882	0.009120
Absolute Change at 12 Months after Intervention 1	-0.001237	(-0.002435, -0.000040)	0.007882	0.009120
Relative Change (Percent) at 12 Months after Intervention 1	-13.57	(-25.66, -1.47)	0.007882	0.009120



Table 2I. Absolute and Relative Changes in Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹ Compared with Expected Rates Derived from Baseline Trend, by Race

Outcome Measure	Beta Estimate	95% Confidence Interval	Predicted Rate (With Intervention)	Extrapolated Rate (Without Intervention)
Race				
White				
Absolute Change at 6 Months after Intervention 1	-0.000538	(-0.000955, -0.000121)	0.011643	0.012180
Relative Change (Percent) at 6 Months after Intervention 1	-4.42	(-7.44, -1.40)	0.011643	0.012180
Absolute Change at 12 Months after Intervention 1	-0.001076	(-0.001909, -0.000242)	0.011571	0.012647
Relative Change (Percent) at 12 Months after Intervention 1	-8.51	(-14.17, -2.84)	0.011571	0.012647



Table 2m. Absolute and Relative Changes in Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹ Compared with Expected Rates Derived from Baseline Trend

			Predicted Rate	Extrapolated Rate
Outcome Measure	Beta Estimate	95% Confidence Interval	(With Intervention)	(Without Intervention)
Absolute Change at 6 Months after Intervention 1	-0.001766	(-0.002838, -0.000695)	0.012212	0.013979
Relative Change (Percent) at 6 Months after Intervention 1	-12.64	(-19.74, -5.53)	0.012212	0.013979
Absolute Change at 12 Months after Intervention 1	-0.001766	(-0.002838, -0.000695)	0.012212	0.013979
Relative Change (Percent) at 12 Months after Intervention 1	-12.64	(-19.74, -5.53)	0.012212	0.013979



Table 2n. Absolute and Relative Changes in Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹ Compared with Expected Rates Derived from Baseline Trend, by Age Group

			Predicted Rate	Extrapolated Rate
Outcome Measure	Beta Estimate	95% Confidence Interval	(With Intervention)	(Without Intervention)
Age Group (Years)				
18-45				
Absolute Change at 6 Months after Intervention 1	-0.002363	(-0.003422, -0.001304)	0.011447	0.013810
Relative Change (Percent) at 6 Months after Intervention 1	-17.11	(-24.03, -10.19)	0.011447	0.013810
Absolute Change at 12 Months after Intervention 1	-0.002363	(-0.003422, -0.001304)	0.011447	0.013810
Relative Change (Percent) at 12 Months after Intervention 1	-17.11	(-24.03, -10.19)	0.011447	0.013810
46-64				
Absolute Change at 6 Months after Intervention 1	-0.001866	(-0.003040, -0.000692)	0.013491	0.015357
Relative Change (Percent) at 6 Months after Intervention 1	-12.15	(-19.26, -5.05)	0.013491	0.015357
Absolute Change at 12 Months after Intervention 1	-0.001866	(-0.003040, -0.000692)	0.013491	0.015357
Relative Change (Percent) at 12 Months after Intervention 1	-12.15	(-19.26, -5.05)	0.013491	0.015357
65+				
Absolute Change at 6 Months after Intervention 1	0.000000	(0.000000, 0.000000)	0.010947	0.010947
Relative Change (Percent) at 6 Months after Intervention 1	0.00	(0.00, 0.00)	0.010947	0.010947
Absolute Change at 12 Months after Intervention 1	0.000000	(0.000000, 0.000000)	0.011079	0.011079
Relative Change (Percent) at 12 Months after Intervention 1	0.00	(0.00, 0.00)	0.011079	0.011079



Table 20. Absolute and Relative Changes in Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹ Compared with Expected Rates Derived from Baseline Trend, by Sex

Outcome Measure	Beta Estimate	95% Confidence Interval	Predicted Rate (With Intervention)	Extrapolated Rate (Without Intervention)
Sex			((
Female				
Absolute Change at 6 Months after Intervention 1	-0.001603	(-0.002655, -0.000552)	0.012273	0.013876
Relative Change (Percent) at 6 Months after Intervention 1	-11.55	(-18.62, -4.49)	0.012273	0.013876
Absolute Change at 12 Months after Intervention 1	-0.001603	(-0.002655, -0.000552)	0.012273	0.013876
Relative Change (Percent) at 12 Months after Intervention 1	-11.55	(-18.62, -4.49)	0.012273	0.013876
Male				
Absolute Change at 6 Months after Intervention 1	-0.002120	(-0.003219, -0.001021)	0.012074	0.014194
Relative Change (Percent) at 6 Months after Intervention 1	-14.93	(-22.01, -7.86)	0.012074	0.014194
Absolute Change at 12 Months after Intervention 1	-0.002120	(-0.003219, -0.001021)	0.012074	0.014194
Relative Change (Percent) at 12 Months after Intervention 1	-14.93	(-22.01, -7.86)	0.012074	0.014194



Table 2p. Absolute and Relative Changes in Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹ Compared with Expected Rates Derived from Baseline Trend, by Race

Outcome Measure	Beta Estimate	95% Confidence Interval	Predicted Rate (With Intervention)	Extrapolated Rate (Without Intervention)
Race			(,	(,
Unknown				
Absolute Change at 6 Months after Intervention 1	-0.002918	(-0.004052, -0.001785)	0.013761	0.016679
Relative Change (Percent) at 6 Months after Intervention 1	-17.50	(-23.61, -11.39)	0.013761	0.016679
Absolute Change at 12 Months after Intervention 1	-0.002918	(-0.004052, -0.001785)	0.013761	0.016679
Relative Change (Percent) at 12 Months after Intervention 1	-17.50	(-23.61, -11.39)	0.013761	0.016679
American Indian/Alaska Native				
Absolute Change at 6 Months after Intervention 1	0.000000	(0.000000, 0.000000)	0.009957	0.009957
Relative Change (Percent) at 6 Months after Intervention 1	0.00	(0.00, 0.00)	0.009957	0.009957
Absolute Change at 12 Months after Intervention 1	0.000000	(0.000000, 0.000000)	0.009957	0.009957
Relative Change (Percent) at 12 Months after Intervention 1	0.00	(0.00, 0.00)	0.009957	0.009957
Asian				
Absolute Change at 6 Months after Intervention 1	0.002219	(0.000968, 0.003470)	0.011527	0.009308
Relative Change (Percent) at 6 Months after Intervention 1	23.84	(8.40, 39.28)	0.011527	0.009308
Absolute Change at 12 Months after Intervention 1	0.002219	(0.000968, 0.003470)	0.011527	0.009308
Relative Change (Percent) at 12 Months after Intervention 1	23.84	(8.40, 39.28)	0.011527	0.009308
Black/African American				
Absolute Change at 6 Months after Intervention 1	0.000000	(0.000000, 0.000000)	0.010809	0.010809
Relative Change (Percent) at 6 Months after Intervention 1	0.00	(0.00, 0.00)	0.010809	0.010809
Absolute Change at 12 Months after Intervention 1	0.000000	(0.000000, 0.000000)	0.010809	0.010809
Relative Change (Percent) at 12 Months after Intervention 1	0.00	(0.00, 0.00)	0.010809	0.010809
Native Hawaiian/Other Pacific Islander				
Absolute Change at 6 Months after Intervention 1	-0.001574	(-0.002755, -0.000392)	0.007897	0.009471
Relative Change (Percent) at 6 Months after Intervention 1	-16.62	(-27.89, -5.34)	0.007897	0.009471
Absolute Change at 12 Months after Intervention 1	-0.001574	(-0.002755, -0.000392)	0.007897	0.009471
Relative Change (Percent) at 12 Months after Intervention 1	-16.62	(-27.89, -5.34)	0.007897	0.009471




Table 2p. Absolute and Relative Changes in Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing among LABA-Naive Patients with Poorly Controlled Asthma in the Sentinel Distributed Database (SDD) after June 2, 2010¹ Compared with Expected Rates Derived from Baseline Trend, by Race

Outcome Measure	Beta Estimate	95% Confidence Interval	Predicted Rate (With Intervention)	Extrapolated Rate (Without Intervention)
Race				
White				
Absolute Change at 6 Months after Intervention 1	-0.000432	(-0.000846, -0.000018)	0.011714	0.012146
Relative Change (Percent) at 6 Months after Intervention 1	-3.56	(-6.64, -0.47)	0.011714	0.012146
Absolute Change at 12 Months after Intervention 1	-0.000864	(-0.001693, -0.000035)	0.011637	0.012501
Relative Change (Percent) at 12 Months after Intervention 1	-6.91	(-12.78, -1.04)	0.011637	0.012501

¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model. An anticipatory period starting from February 2, 2010 (rounded to the nearest subsequent month) up to the month prior to the intervention was implemented. Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete




Figure 1. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 2. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Age Group = 18-45



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 3. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Age Group = 46-64



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 4. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Age Group = 65+



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 5. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Sex = Female



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 6. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Sex = Male



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 7. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Race = Unknown



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 8. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Race = American Indian/Alaska Native



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 9. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Race = Asian



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 10. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Race = Black/African American



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 11. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Race = Native Hawaiian/Other Pacific Islander



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 12. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 1 Day of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Race = White



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 13. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 14. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Age Group = 18-45



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 15. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Age Group = 46-64



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 16. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Age Group = 65+



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 17. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Sex = Female



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 18. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Sex = Male



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 19. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Race = Unknown



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 20. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Race = American Indian/Alaska Native



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 21. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Race = Asian



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 22. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Race = Black/African American



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 23. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Race = Native Hawaiian/Other Pacific Islander



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 24. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 50% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Race = White



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 25. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 26. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Age Group = 18-45



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 27. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Age Group = 46-64



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 28. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Age Group = 65+



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 29. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Sex = Female



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 30. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Sex = Male



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 31. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Race = Unknown



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 32. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Race = American Indian/Alaska Native



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 33. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Race = Asian



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 34. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Race = Black/African American



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 35. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Race = Native Hawaiian/Other Pacific Islander



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 36. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with at Least 75% Duration Overlap with Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Race = White



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 37. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 38. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Age Group = 18-45



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 39. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Age Group = 46-64



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 40. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Age Group = 65+



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 41. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Sex = Female



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 42. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Sex = Male



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 43. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Race = Unknown



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 44. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Race = American Indian/Alaska Native



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 45. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Race = Asian



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 46. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Race = Black/African American



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.




Figure 47. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Race = Native Hawaiian/Other Pacific Islander



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.



Figure 48. Proportion of Incident Long-Acting Beta-2 Agonists (LABA) Users with Same-Day Dispensing of Asthma Controller Medication (ACM) or Fixed-Dose Combination (FDC) LABA Dispensing Among LABA-Naive Patients with Poorly Controlled Asthma Before and After June 2, 2010^{1,2}, where Race = White



¹The ITS model is performed with rounding to the nearest subsequent month for June 2, 2010 as the start of drug safety communication. Data from January 1, 2007 to September 30, 2015 is used to create the model.



DP ID	Start Date ¹	End Date ¹
DP01	1/1/2004	8/31/2019
DP02	1/1/2008	3/31/2019
DP03	1/1/2000	7/31/2019
DP04	1/1/2006	6/30/2019
DP05	1/1/2000	4/30/2019
DP06	1/1/2000	2/28/2019
DP07	1/1/2000	6/30/2019
DP08	1/1/2000	3/31/2019
DP09	1/1/2000	1/31/2019
DP10	1/1/2010	6/30/2019
DP11	1/1/2012	6/30/2018
DP12	1/1/2008	9/30/2019
DP13	1/1/2005	7/31/2018
DP14	1/1/2000	12/31/2017
DP15	1/1/2000	4/30/2018
DP16	6/1/2007	7/31/2019

Appendix A. Start and End Dates for Each Data Partner (DP) up to Request Distribution Date (April 6, 2020)

¹The start and end dates are based on the minimum and maximum dates within each DP. The month with the maximum date must have at least 80% of the number of records in the previous month.



Appendix B. List of Generic and Brand Names of Medical Products Used to Define Single Ingredient (SI) and Fixed Dose Combination (FDC) Long-Acting Beta-2 Agonist (LABA)s and Other non-LABA Asthma Controller Medication (ACM) in this Request

Generic Name	Brand Name
SI-L	LABA
formoterol fumarate	Foradil Aerolizer
salmeterol xinafoate	Serevent
salmeterol xinafoate	Serevent Diskus
FDC	-LABA
budesonide/formoterol fumarate	Symbicort
fluticasone furoate/umeclidinium bromide/vilanterol trifenat	Trelegy Ellipta
fluticasone furoate/vilanterol trifenatate	Breo Ellipta
fluticasone propionate/salmeterol xinafoate	AirDuo RespiClick
fluticasone propionate/salmeterol xinafoate	fluticasone propion-salmeterol
fluticasone propionate/salmeterol xinafoate	Advair Diskus
fluticasone propionate/salmeterol xinafoate	Wixela Inhub
fluticasone propionate/salmeterol xinafoate	Advair HFA
mometasone furoate/formoterol fumarate	Dulera
Inhaled Co	rticosteroids
beclomethasone dipropionate	Qvar
beclomethasone dipropionate	Qvar RediHaler
budesonide	Pulmicort Flexhaler
budesonide	Pulmicort Turbuhaler
ciclesonide	Alvesco
flunisolide	Aerobid
flunisolide	Aerospan
flunisolide/menthol	Aerobid-M
fluticasone furoate	Arnuity Ellipta
fluticasone propionate	Flovent
fluticasone propionate	ArmonAir RespiClick
fluticasone propionate	Flovent Diskus
fluticasone propionate	Flovent HFA
mometasone furoate	Asmanex Twisthaler
mometasone furoate	Asmanex HFA
triamcinolone acetonide	Azmacort
Leukotrier	ne Modifiers
montelukast sodium	montelukast
montelukast sodium	Singulair
zafirlukast	Accolate
zafirlukast	zafirlukast
zileuton	Zyflo
zileuton	zileuton
zileuton	Zyflo CR



Appendix B. List of Generic and Brand Names of Medical Products Used to Define Single Ingredient (SI) and Fixed Dose Combination (FDC) Long-Acting Beta-2 Agonist (LABA)s and Other non-LABA Asthma Controller Medication (ACM) in this Request

Generic Name	Brand Name
	Chromones
cromolyn sodium	Intal
cromolyn sodium	Intal 112
cromolyn sodium	Intal 200
nedocromil sodium	Tilade
Ora	al Corticosteroids
cortisone acetate	cortisone
dexamethasone	Dexamethasone Intensol
dexamethasone	Baycadron
dexamethasone	Decadron
dexamethasone	dexamethasone
dexamethasone	DexPak 10 day
dexamethasone	DexPak 13 Day
dexamethasone	DexPak 6 Day
dexamethasone	Dxevo
dexamethasone	HiDex
dexamethasone	LoCort
dexamethasone	TaperDex
dexamethasone	Zema-Pak
dexamethasone	ZoDex
dexamethasone	ZonaCort
methylprednisolone	Medrol
methylprednisolone	methylprednisolone
methylprednisolone	Medrol (Pak)
methylprednisolone	Meprolone Unipak
methylprednisolone	Methylpred
methylprednisolone	Methylpred DP
prednisolone	prednisolone
prednisolone	Prelone
prednisolone	Millipred
prednisolone	Millipred DP
prednisolone acetate	Flo-Pred
prednisolone sodium phosphate	Millipred
prednisolone sodium phosphate	prednisolone sodium phosphate
prednisolone sodium phosphate	Orapred
prednisolone sodium phosphate	Veripred 20
prednisolone sodium phosphate	Bubbli-Pred
prednisolone sodium phosphate	Pediapred
prednisolone sodium phosphate	Orapred ODT
Prednisolone Sodium Phosphate/Peak Flow Meter	Asmalpred
Prednisolone Sodium Phosphate/Peak Flow Meter	Asmalpred Plus
prednisone	



Appendix B. List of Generic and Brand Names of Medical Products Used to Define Single Ingredient (SI) and Fixed Dose Combination (FDC) Long-Acting Beta-2 Agonist (LABA)s and Other non-LABA Asthma Controller Medication (ACM) in this Request

Generic Name	Brand Name	
prednisone	prednisone	
prednisone	Deltasone	
prednisone	Rayos	
prednisone	Sterapred DS	
prednisone	Sterapred	
	Immunomodulators	
benralizumab	Fasenra	
dupilumab	Dupixent	
mepolizumab	Nucala	
omalizumab	Xolair	
reslizumab	Cinqair	
	Methylxanthines	
aminophylline	aminophylline	
dyphylline	Dylix	
dyphylline	Lufyllin	
theophylline anhydrous	Slo-Bid Gyrocaps	
theophylline anhydrous	TheoCap	
theophylline anhydrous	theophylline	
theophylline anhydrous	Theo-24	
theophylline anhydrous	Elixophyllin	
theophylline anhydrous	Quibron-T	
theophylline anhydrous	Uniphyl	
theophylline anhydrous	Theochron	
theophylline anhydrous	Quibron-T/SR	



Code	Description	Code Category	Code Type
	Asthma		
493	Asthma	Diagnosis	ICD-9-CM
493.0	Extrinsic asthma	Diagnosis	ICD-9-CM
493.00	Extrinsic asthma, unspecified	Diagnosis	ICD-9-CM
493.01	Extrinsic asthma with status asthmaticus	Diagnosis	ICD-9-CM
193.02	Extrinsic asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM
93.1	Intrinsic asthma	Diagnosis	ICD-9-CM
93.10	Intrinsic asthma, unspecified	Diagnosis	ICD-9-CM
93.11	Intrinsic asthma with status asthmaticus	Diagnosis	ICD-9-CM
93.12	Intrinsic asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM
93.2	Chronic obstructive asthma	Diagnosis	ICD-9-CM
93.20	Chronic obstructive asthma, unspecified	Diagnosis	ICD-9-CM
93.21	Chronic obstructive asthma with status asthmaticus	Diagnosis	ICD-9-CM
93.22	Chronic obstructive asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM
93.8	Other forms of asthma	Diagnosis	ICD-9-CM
93.81	Exercise induced bronchospasm	Diagnosis	ICD-9-CM
93.82	Cough variant asthma	Diagnosis	ICD-9-CM
93.9	Unspecified asthma	Diagnosis	ICD-9-CM
93.90	Asthma, unspecified, unspecified status	Diagnosis	ICD-9-CM
93.91	Asthma, unspecified with status asthmaticus	Diagnosis	ICD-9-CM
193.92	Asthma, unspecified, with (acute) exacerbation	Diagnosis	ICD-9-CM
	Chronic Obstructive Pulmonary Disease (COPD)	
90	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-9-CM
91	Chronic bronchitis	Diagnosis	ICD-9-CM
91.0	Simple chronic bronchitis	Diagnosis	ICD-9-CM
91.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-9-CM
91.2	Obstructive chronic bronchitis	Diagnosis	ICD-9-CM
91.20	Obstructive chronic bronchitis, without exacerbation	Diagnosis	ICD-9-CM
91.21	Obstructive chronic bronchitis, with (acute) exacerbation	Diagnosis	ICD-9-CM
91.22	Obstructive chronic bronchitis with acute bronchitis	Diagnosis	ICD-9-CM
91.8	Other chronic bronchitis	Diagnosis	ICD-9-CM
91.9	Unspecified chronic bronchitis	Diagnosis	ICD-9-CM
92	Emphysema	Diagnosis	ICD-9-CM
92.0	Emphysematous bleb	Diagnosis	ICD-9-CM
92.8	Other emphysema	Diagnosis	ICD-9-CM
93.2	Chronic obstructive asthma	Diagnosis	ICD-9-CM
93.20	Chronic obstructive asthma, unspecified	Diagnosis	ICD-9-CM
93.21	Chronic obstructive asthma with status asthmaticus	Diagnosis	ICD-9-CM
193.22	Chronic obstructive asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM
196	Chronic airway obstruction, not elsewhere classified	Diagnosis	ICD-9-CM

Appendix C. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) Diagnosis Codes Used to Define Inclusion and Exclusion Criteria in this Request



Code	Description	Code Category	Code Type
	Cystic Fibrosis		
277.0	Cystic fibrosis	Diagnosis	ICD-9-CM
277.00	Cystic fibrosis without mention of meconium ileus	Diagnosis	ICD-9-CM
277.01	Cystic fibrosis with meconium ileus	Diagnosis	ICD-9-CM
277.02	Cystic fibrosis with pulmonary manifestations	Diagnosis	ICD-9-CM
277.03	Cystic fibrosis with gastrointestinal manifestations	Diagnosis	ICD-9-CM
277.09	Cystic fibrosis with other manifestations	Diagnosis	ICD-9-CM
	Bronchiectasis		
494	Bronchiectasis	Diagnosis	ICD-9-CM
494.0	Bronchiectasis without acute exacerbation	Diagnosis	ICD-9-CM
494.1	Bronchiectasis with acute exacerbation	Diagnosis	ICD-9-CM
	Pulmonary Hypertension or Embolism	l	
415.1	Pulmonary embolism and infarction	Diagnosis	ICD-9-CM
415.11	latrogenic pulmonary embolism and infarction	Diagnosis	ICD-9-CM
415.12	Septic pulmonary embolism	Diagnosis	ICD-9-CM
415.13	Saddle embolus of pulmonary artery	Diagnosis	ICD-9-CM
415.19	Other pulmonary embolism and infarction	Diagnosis	ICD-9-CM
416.0	Primary pulmonary hypertension	Diagnosis	ICD-9-CM
	Bronchopulmonary Dysplasia		
770.7	Chronic respiratory disease arising in the perinatal period	Diagnosis	ICD-9-CM
	Congestive Heart Failure		
428	Heart failure	Diagnosis	ICD-9-CM
428.0	Congestive heart failure, unspecified	Diagnosis	ICD-9-CM
428.1	Left heart failure	Diagnosis	ICD-9-CM
428.2	Systolic heart failure	Diagnosis	ICD-9-CM
428.20	Unspecified systolic heart failure	Diagnosis	ICD-9-CM
428.21	Acute systolic heart failure	Diagnosis	ICD-9-CM
428.22	Chronic systolic heart failure	Diagnosis	ICD-9-CM
428.23	Acute on chronic systolic heart failure	Diagnosis	ICD-9-CM
428.3	Diastolic heart failure	Diagnosis	ICD-9-CM
428.30	Unspecified diastolic heart failure	Diagnosis	ICD-9-CM
428.31	Acute diastolic heart failure	Diagnosis	ICD-9-CM
428.32	Chronic diastolic heart failure	Diagnosis	ICD-9-CM
428.33	Acute on chronic diastolic heart failure	Diagnosis	ICD-9-CM
428.4	Combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.40	Unspecified combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.41	Acute combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.42	Chronic combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.43	Acute on chronic combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.9	Unspecified heart failure	Diagnosis	ICD-9-CM

Appendix C. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) Diagnosis Codes Used to Define Inclusion and Exclusion Criteria in this Request



Appendix D. List of Generic and Brand Names of Medical Products Used to Define Poorly Controlled Asthma in this Request

Generic Name	Brand Name
	Inhaled Corticosteroids
beclomethasone dipropionate	Qvar
beclomethasone dipropionate	Qvar RediHaler
budesonide	Pulmicort Flexhaler
budesonide	Pulmicort Turbuhaler
ciclesonide	Alvesco
flunisolide	Aerobid
lunisolide	Aerospan
flunisolide/menthol	Aerobid-M
fluticasone furoate	Arnuity Ellipta
fluticasone propionate	Flovent
luticasone propionate	ArmonAir RespiClick
fluticasone propionate	Flovent Diskus
fluticasone propionate	Flovent HFA
mometasone furoate	Asmanex Twisthaler
mometasone furoate	Asmanex HFA
triamcinolone acetonide	Azmacort
	Leukotriene Modifiers
montelukast sodium	montelukast
montelukast sodium	Singulair
zafirlukast	Accolate
zafirlukast	zafirlukast
zileuton	Zyflo
zileuton	zileuton
zileuton	Zyflo CR
	Oral Corticosteroids
cortisone acetate	cortisone
dexamethasone	Dexamethasone Intensol
dexamethasone	Baycadron
dexamethasone	Decadron
dexamethasone	dexamethasone
dexamethasone	DexPak 10 day
dexamethasone	DexPak 13 Day
dexamethasone	DexPak 6 Day
dexamethasone	Dxevo
dexamethasone	HiDex
dexamethasone	LoCort
dexamethasone	TaperDex
dexamethasone	Zema-Pak
dexamethasone	ZoDex
dexamethasone	ZonaCort
methylprednisolone	Medrol
methylprednisolone	methylprednisolone



Appendix D. List of Generic and Brand Names of Medical Products Used to Define Poorly Controlled Asthma in this Request

Generic Name	Brand Name
methylprednisolone	Meprolone Unipak
methylprednisolone	Methylpred
methylprednisolone	Methylpred DP
prednisolone	prednisolone
prednisolone	Prelone
prednisolone	Millipred
prednisolone	Millipred DP
prednisolone acetate	Flo-Pred
prednisolone sodium phosphate	Millipred
prednisolone sodium phosphate	prednisolone sodium phosphate
prednisolone sodium phosphate	Orapred
prednisolone sodium phosphate	Veripred 20
prednisolone sodium phosphate	Bubbli-Pred
prednisolone sodium phosphate	Pediapred
prednisolone sodium phosphate	Orapred ODT
Prednisolone Sodium Phosphate/Peak Flow Meter	Asmalpred
Prednisolone Sodium Phosphate/Peak Flow Meter	Asmalpred Plus
prednisone	Prednisone Intensol
prednisone	prednisone
prednisone	Deltasone
prednisone	Rayos
prednisone	Sterapred DS
prednisone	Sterapred
Short-Acti	ng Beta-2 Agonists (SABA)
albuterol	albuterol
albuterol	albuterol (refill)
albuterol	Proventil
albuterol	Proventil (Refill)
albuterol	Ventolin
albuterol sulfate	ProAir RespiClick
albuterol sulfate	albuterol sulfate
albuterol sulfate	ProAir HFA
albuterol sulfate	Proventil HFA
albuterol sulfate	Ventolin HFA
levalbuterol tartrate	levalbuterol tartrate
levalbuterol tartrate	Xopenex HFA
metaproterenol sulfate	Alupent
pirbuterol acetate	Maxair Autohaler



This request executed the Cohort Identification and Descriptive Analysis (CIDA) tool, version 9.3.1, to estimate incident use of long-acting beta-2 agonist (LABA) with and without a long-term asthma controller medication (ACM) among asthma patients before and after drug safety communications (DSCs) issued on June 2, 2010 in the Sentinel Distributed Database (SDD). The purpose of the request is to test the newly added functionality for interrupted time series (ITS) analysis, which creates regression models of rates over time after truncating follow-up time at a pre-specified intervention date.

Query Period:	January 01, 2006 - September 30, 2015
Coverage Requirement:	Medical & Drug Coverage
Pre-Index Enrollment Requirement:	See below
Post-Index Enrollment Requirement:	N/A
Enrollment Gap:	45 days
Age Groups:	18-45, 46-64, 65+ years
Sex Groups:	Male, female
Stratifications:	Age group, sex, race, ethnicity, Census Bureau regions
Censor Output Categorization:	0-30, 31-60, 61-90, 91-120, 121-183, 184-365, 366-730, 730+
Restrictions:	N/A
Envelope Macro:	No reclassification
Features:	Interrupted time series (ITS) analysis, distribution of index-defining codes, multiple events/overlap, censoring output

Freeze Data: Yes

	Cohorts 8-10				
		Recommendation 2			
		Poorly controlled LABA			
	Scenario 8	Scenario 6	Scenario 7		
Group Name	grp5_pcasthma	grp456_acm2	grp456_fdc2		
ITS Group	Primary	Secondary			
Rate Denominator Definition	Poorly controlled asthma patients	N//	4		
Rate Denominator	Number of eligible members	N//	4		
Rate Numerator Definition	N/A	Incident LABA users con	current with ACM use		
Rate Numerator	N/A	Number of adherent patients			
Pre-Index Enrollment Requirement	365 days	0 days	365 days		

TS Analysis Groups



			Cohorts 8-10	
			Recommendation 2	
			Poorly controlled LABA	
		Scenario 8	Scenario 6	Scenario 7
	Exposure	All LABA products	Non-LABA asthma controller	FDC LABA
		(Single-ingredient (SI) OR fixed-dose	medication (ACM) (ICS, leukotriene	
		combination (FDC))	modifier, chromones, oral systemic	
			corticosteroids, immunomodulators,	
			and methylxanthines)	
	Care Setting	N/A	N/A	N/A
	Incident with Respect To	All LABA products (SI or FDC)		
)	Washout	183 days	0 days	0 days
	Exposure Episode Truncation Criteria	*Death	*Death	*Death
2		*Data Partner (DP) end date	*DP end date	*DP end date
ulug/ Lypusule		*Query end date	*Query end date	*Query end date
	Cohort Definition	Only the first valid treatment	Cohort includes all valid exposure	Cohort includes all valid exposure
		episode during the query period (01)	episodes during the query period (02)	episodes during the query period (02
	Prevalent Cohort Creation?	Yes	N/A	N/A
	Exposure Episode Gap	25% previous days' supply	25% previous days' supply	25% previous days' supply
	Exposure Extension Period	0 days	0 days	0 days
	Minimum Episode Duration	1 day	1 day	1 day
	Minimum Days Supplied	1 day	1 day	1 day
L	Intention-to-Treat Days	N/A	N/A	N/A
	Conditions	*Chronic obstructive pulmonary		*COPD
		disease (COPD)		*Cystic fibrosis
		*Cystic fibrosis		*Bronchiectasis
5		*Bronchiectasis		*Pulmonary hypertension or
		*Pulmonary hypertension or		embolism
200		embolism		*Bronchopulmonary dysplasia
2		*Bronchopulmonary dysplasia		*Congestive heart failure
		*Congestive heart failure		-
2	Include or Exclude	Exclusion		Exclusion
2	Care Setting/Principal Diagnosis (PDX)	Any		Any
	Lookback Period	(-365, 0)		(-365, 0)
	Number of Code Occurrences	1 instance		1 instance



		Cohorts 8-10		
		Recommendation 2		
	Poorly controlled LABA			
	Scenario 8	Scenario 6	Scenario 7	
Conditions	Asthma (493.xx)			
Include or Exclude	Inclusion			
Care Setting/PDX	IP*, ED*, AV*, OA*			
Lookback Period	(-365, 0) days			
Number of Code Occurrences	1 instance if (IP*, ED*)			
	2 instances if (AV*, OA*)			
	· · ·			
Conditions	Poorly controlled asthma			
	(ICS or LM dispensing)			
	(lookback period: days supply)			
Include or Exclude	Inclusion			
Care Setting/PDX	N/A			
Lookback Period	(-90, -1) days			
Number of Code Occurrences	1 instance			
	OR			
Conditions	Poorly controlled asthma			
	(asthma (493.xx))			
Include or Exclude	Inclusion			
Care Setting/PDX	IP*, ED*			
Lookback Period	(-90, -1) days			
Number of Code Occurrences	1 instance			
	OR			
Conditions	Poorly controlled asthma			
	(oral corticosteroids dispensing of			
	21 days' supply or smaller) (combo)			
	(lookback period: days supply)			
Include or Exclude	Inclusion			
Care Setting/PDX	N/A			
Lookback Period	(-90, -1) days			
Number of Code Occurrences	2 instances			



		Cohorts 8-10		
		Recommendation 2		
		Poorly controlled LABA		
	Scenario 8	Scenario 6	Scenario 7	
-	OR			
Conditions	Poorly controlled asthma			
	(SABA canisters)			
	(lookback period: dispensing date)			
Include or Exclude	Inclusion			
Care Setting/PDX	N/A			
Lookback Period	(-183 <i>,</i> -1) days			
Number of Code Occurrences	3 instances			
_ F				
Same Day Dispensing (Days Supplied)	Sum	Sum	Sum	
Same Day Dispensing (Amount Supplied) Range of Allowable Days Supplied Range of Allowable Amount Supplied	Sum	Sum	Sum	
Range of Allowable Days Supplied	N/A	N/A	N/A	
Range of Allowable Amount Supplied	N/A	N/A	N/A	
Overlap Percentage Processing	Default	Default	Default	
Multiple Events or Overlap?		Overlap (M78_pc_laba)		
Group Identifier	Primary	Secor	ndary	
Multiple Events or Overlap? Group Identifier Observation Window Around Primary Episode Secondary Episode to Use for Time Metrics Minimum Cutoff to be Considered Adherent Categories for Overlap Metrics Primary Episode Categories		(Index date, episode end)		
Secondary Episode to Use for Time Metrics		N/A		
Minimum Cutoff to be Considered Adherent		1 day		
Categories for Overlap Metrics)-<25 25-<50 50-<75 >=75 =100%		
Primary Episode Categories		1-90 91-120 121-183 184-365 366-	730 731+	
Adherence Name	Incident LABA Users	50% concurrent with ACM Use (N	178_pc_laba_50)	
Minimum/Maximum Episode Length or		50% minimum		
Overlap Time (Overlap)				
Minimum/Maximum Secondary Episode		N/A		
Count (Multiple Events)				



			Cohorts 8-10	
			Recommendation 2	
			Poorly controlled LABA	
		Scenario 8	Scenario 6	Scenario 7
Adherence	Minimum/Maximum Secondary Episode Gap (Multiple Events)		N/A	
Adhe	Minimum/Maximum Time to Secondary Episode Count (Multiple Events)		N/A	
-				
	Adherence Name	Incident LABA	Users 75% concurrent with ACM Use (N	178_pc_laba_75)
	Minimum/Maximum Episode Length or Overlap Time (Overlap)		75% minimum	
Adherence	Minimum/Maximum Secondary Episode Count (Multiple Events)		N/A	
Adh	Minimum/Maximum Secondary Episode Gap (Multiple Events)		N/A	
	Minimum/Maximum Time to Secondary Episode Count (Multiple Events)		N/A	
_				
	Data Range Start, End		Full query period	
	Anticipatory Date 1 Start		February 2010	
	Intervention Date 1		June 2010	
	Anticipatory Date 2 Start		N/A	
sis	Intervention Date 2		N/A	
Analysis	Interval Length		Month	
An	P-Value		0.05	
ITS	Autoregression Lag		12 months	
	Autoregression Model Parameter Cutoff		0.2	
	Time Points at Which to Report Difference Metrics	Janı	ary 2011, June 2011, January 2012, June	2012
L	Continuous Enrollment Required?		No	



		Cohorts 8-10	
Γ		Recommendation 2	
	Poorly controlled LABA		
	Scenario 8	Scenario 6	Scenario 7
Covariates		SI-LABA	
		FDC	
		All LABA	
		non-LABA ACM	
Care Setting/PDX		N/A	
Covariate Evaluation Window		(-183, -1) days	
· · · · · · · · · · · · · · · · · · ·			
Covariates		non-LABA ACM	
Care Setting/PDX	N/A		
Covariate Evaluation Window	(-365, -184) dyas		
·			
Covariates		SI-LABA	
		FDC	
		All LABA	
		non-LABA ACM	
Care Setting/PDX		N/A	
Covariate Evaluation Window		(0, 0) days	
Comorbidity Score Evaluation Window		(-365, 0) days	
Medical Utilization Evaluation Window		(-365, 0) days	
Medical Utilization Care Setting		IP, IS, AV, OA, ED	
Drug Utilization Evaluation Window		(-365, 0) days	



			Cohort 11	
			Recommendation 2	
		Poorly controlled LABA, SI-LABA in ACM presence (Measures 11, 12)		
	_	Scenario 8	Scenario 6	Scenario 7
	Group Name	grp5_pcasthma	grp456_acm2	grp456_fdc2
	ITS Group	Primary	Seco	ndary
Groups	Rate Denominator Definition	Poorly controlled asthma patients	N	/A
25	Rate Denominator	Number of eligible members	N	/A
Ŭ	Rate Numerator Definition	N/A	Incident LABA users co	ncurrent with ACM use
	Rate Numerator	N/A	Number of adl	nerent patients
Г	Pre-Index Enrollment Requirement	365 days	0 days	365 days
			•	•
	Exposure	All LABA products (SI or FDC)	Non-LABA ACM (ICS, leukotriene modifier, chromones, oral systemic corticosteroids, immunomodulators, and methylxanthines)	FDC LABA
	Care Setting	N/A	N/A	N/A
	Incident with Respect To	All LABA products (SI or FDC)		
	Washout	183 days	0 days	0 days
sure	Exposure Episode Truncation Criteria	*Death	*Death	*Death
Drug/Exposure		*DP end date *Query end date	*DP end date *Query end date	*DP end date *Query end date
Drug	Cohort Definition	Only the first valid treatment episode during the query period (01)	Cohort includes all valid exposure episodes during the query period (02)	Cohort includes all valid exposure episodes during the query period (C
	Prevalent Cohort Creation?	Yes	N/A	N/A
	Exposure Episode Gap	25% previous days' supply	25% previous days' supply	25% previous days' supply
	Exposure Extension Period	0 days	0 days	0 days
	Minimum Episode Duration	1 day	1 day	1 day
	Minimum Days Supplied	1 day	1 day	1 day
	Intention-to-Treat Days	N/A	N/A	N/A



			Cohort 11			
			Recommendation 2			
		Poorly controlled I	Poorly controlled LABA, SI-LABA in ACM presence (Measures 11, 12)			
		Scenario 8	Scenario 6	Scenario 7		
Γ	Conditions	*COPD		*COPD		
a		*Cystic fibrosis		*Cystic fibrosis		
teri		*Bronchiectasis		*Bronchiectasis		
Ċ		*Pulmonary hypertension or		*Pulmonary hypertension or		
ion		embolism		embolism		
silus		*Bronchopulmonary dysplasia		*Bronchopulmonary dysplasia		
/Exc		*Congestive heart failure		*Congestive heart failure		
Inclusion/Exclusion Criteria	Include or Exclude	Exclusion		Exclusion		
clus	Care Setting/PDX	Any		Any		
느	Lookback Period	(-365, 0) days		(-365, 0) days		
	Number of Code Occurrences	1 instance		1 instance		
	Conditions	Asthma (493.xx)				
	Include or Exclude	Inclusion				
	Care Setting/PDX	IP*, ED*, AV*, OA*				
eria	Lookback Period	(-365, 0) days				
Crit	Number of Code Occurrences	1 instance if (IP*, ED*)				
on (2 instances if (AV*, OA*)				
Inclusion/ Exclusion Criteria						
Exc	Conditions	Poorly controlled asthma				
/uc		(ICS or LM dispensing)				
usic		(lookback period: days supply)				
ncl	Include or Exclude	Inclusion				
	Care Setting/PDX	N/A				
	Lookback Period	(-90, -1) days				
	Number of Code Occurrences	1 instance				
		OR				
ia.	Conditions	Poorly controlled asthma				
Criteria		(asthma (493.xx))				
ັບ	Include or Exclude	Inclusion				



		Cohort 11		
		Recommendation 2		
		Poorly controlled LABA, SI-LABA in ACM presence (Measures 11, 12)		
	Scenario 8	Scenario 6	Scenario 7	
Care Setting/PDX	IP*, ED*			
Lookback Period	(-90, -1) days			
Number of Code Occurrences	1 instance			
	OR			
Conditions	Poorly controlled asthma			
	(oral corticosteroids dispensing of			
	21 days' supply or smaller) (combo)			
	(lookback period: days supply)			
Include or Exclude	Inclusion			
Care Setting/PDX	N/A			
Lookback Period	(-90, -1) days			
Number of Code Occurrences	2 instances			
OR				
Conditions	Poorly controlled asthma			
	(SABA canisters)			
	(lookback period: dispensing date)			
Include or Exclude	Inclusion			
Care Setting/PDX	N/A			
Lookback Period	(-183, -1) days			
Number of Code Occurrences	3 instances			
Same Day Dispensing (Days Supplied)	Sum	Sum	Sum	
Same Day Dispensing (Amount Supplied)	Sum	Sum	Sum	
Range of Allowable Days Supplied	N/A	N/A	N/A	
Range of Allowable Amount Supplied	N/A	N/A	N/A	
Overlap Percentage Processing	Default	Default	Default	
Multiple Events or Overlap?		Overlap		
Group Identifier	Primary	Secon	dary	
Observation Window Around Primary		(Index date, index date)		
Episode				



			Cohort 11		
			Recommendation 2		
		Poorly controlled LABA, SI-LABA in ACM presence (Measures 11, 12)			
_		Scenario 8	Scenario 6	Scenario 7	
5	Secondary Episode to Use for Time Metrics		N/A		
	Minimum Cutoff to be Considered Adherent		N/A		
	Categories for Overlap Metrics	N/A N/A			
Ĺ	Primary Episode Categories				
Г	Adherence Name	Incident I AB	A Lisers SI-LABA in ACM presence (M11	112 nc laba?)	
Adherence Name Incident LABA Users, SI-LABA in ACM presence (M1112_pc_laba2 Minimum/Maximum Episode Length or 1 day minimum					
	Overlap Time (Overlap)		i day minimum		
כ	Minimum/Maximum Secondary Episode	N/A			
ע ע	Count (Multiple Events)				
4	Minimum/Maximum Secondary Episode Gap (Multiple Events)	N/A			
	Minimum/Maximum Time to Secondary	N/A			
	Episode Count (Multiple Events)				
Г	Adherence Name		N/A		
	Minimum/Maximum Episode Length or		N/A N/A		
	Overlap Time (Overlap)		N/A		
2 C	Minimum/Maximum Secondary Episode		N/A		
אמוופו בוורב	Count (Multiple Events)		·		
2	Minimum/Maximum Secondary Episode Gap		N/A		
`	(Multiple Events)				
	Minimum/Maximum Time to Secondary		N/A		
L	Episode Count (Multiple Events)				
2	Data Range Start, End		Full query period		
	Anticipatory Date 1 Start		February 2010		
ſ	Intervention Date 1		June 2010		
ź	Anticipatory Date 2 Start		N/A		



	Cohort 11 Recommendation 2		
	Poorly controlle Scenario 8	d LABA, SI-LABA in ACM presence (Measu Scenario 6	ures 11, 12) Scenario 7
Intervention Date 2	Scenario 8	N/A	Scenario 7
	N/A Month		
2 P-Value	0.05		
P-value	12 months		
Autoregression Lag			
P-Value Autoregression Lag Autoregression Model Parameter Cutoff Time Points at Which to Report Difference	0.2		
	Januar	y 2011, June 2011, January 2012, June 201	.2
Metrics			
Continuous Enrollment Required?		No	
Covariates		SI-LABA	
Care Setting/PDX	N/A		
Covariate Evaluation Window	(-183, -1) days		
		(103, 1) 0003	
Covariates Care Setting/PDX Covariate Evaluation Window	non-LABA ACM		
Care Setting/PDX	N/A		
Covariate Evaluation Window	(-365, -184) days		
Covariates		SI-LABA	
Covariates Care Setting/PDX		N/A	
Covariates			
Covariates Care Setting/PDX Covariate Evaluation Window		N/A (0, 0) days	
Covariates Care Setting/PDX Covariate Evaluation Window Comorbidity Score Evaluation Window		N/A (0, 0) days (-365, 0) days	
Covariates Care Setting/PDX Covariate Evaluation Window		N/A (0, 0) days	